https://trial.medpath.com/news/pricing-dynamics-of-rare-disease-drugs-how-prevalence-and-patient-numbers-shape-market-access 2025-03-25T20:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pricing-dynamics-of-rare-disease-drugs-how-prevalence-and-patient-numbers-shape-market-access 2025-03-25T20:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-s-sunosi-shows-positive-phase-3-results-in-adult-adhd-trial 2025-03-25T20:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axsome-s-sunosi-shows-positive-phase-3-results-in-adult-adhd-trial 2025-03-25T20:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-oral-carbapenem-antibiotic-tebipenem-hbr-succeeds-in-phase-3-trial-setting-stage-for-fda-filing 2025-03-25T20:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-oral-carbapenem-antibiotic-tebipenem-hbr-succeeds-in-phase-3-trial-setting-stage-for-fda-filing 2025-03-25T20:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/dexcom-advances-diabetes-management-with-15-day-cgm-sensor-and-expanded-type-2-applications 2025-03-25T19:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexcom-advances-diabetes-management-with-15-day-cgm-sensor-and-expanded-type-2-applications 2025-03-25T19:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-fingerprint-drug-screening-system-on-track-for-2025-fda-clearance 2025-03-25T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intelligent-bio-solutions-fingerprint-drug-screening-system-on-track-for-2025-fda-clearance 2025-03-25T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-blujepa-first-new-class-of-oral-antibiotic-for-utis-in-nearly-30-years 2025-03-25T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-blujepa-first-new-class-of-oral-antibiotic-for-utis-in-nearly-30-years 2025-03-25T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/linus-health-to-showcase-digital-cognitive-assessment-tools-at-ad-pd-2025-conference 2025-03-25T18:02:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/linus-health-to-showcase-digital-cognitive-assessment-tools-at-ad-pd-2025-conference 2025-03-25T18:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/character-biosciences-secures-93m-to-advance-precision-therapies-for-age-related-macular-degeneration 2025-03-25T17:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/character-biosciences-secures-93m-to-advance-precision-therapies-for-age-related-macular-degeneration 2025-03-25T17:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-unveils-promising-preclinical-data-for-novel-cancer-therapeutics-at-aacr-2025 2025-03-25T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-unveils-promising-preclinical-data-for-novel-cancer-therapeutics-at-aacr-2025 2025-03-25T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/imcheck-s-ict01-shows-unprecedented-complete-remission-rates-in-aml-combination-therapy 2025-03-25T17:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imcheck-s-ict01-shows-unprecedented-complete-remission-rates-in-aml-combination-therapy 2025-03-25T17:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/early-combination-of-statins-and-ezetimibe-could-prevent-thousands-of-heart-attacks-study-finds 2025-03-25T16:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-combination-of-statins-and-ezetimibe-could-prevent-thousands-of-heart-attacks-study-finds 2025-03-25T16:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-abandons-hepatitis-drug-development-following-phase-i-failure-shifts-focus-to-ophthalmology 2025-03-25T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surrozen-abandons-hepatitis-drug-development-following-phase-i-failure-shifts-focus-to-ophthalmology 2025-03-25T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-arjuna-s-shoden-r-ashwagandha-extract-as-natural-health-product 2025-03-25T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-arjuna-s-shoden-r-ashwagandha-extract-as-natural-health-product 2025-03-25T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-scholar-rock-s-bla-for-apitegromab-in-spinal-muscular-atrophy-with-priority-review 2025-03-25T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-scholar-rock-s-bla-for-apitegromab-in-spinal-muscular-atrophy-with-priority-review 2025-03-25T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/nasa-awards-redwire-contract-for-advanced-pharmaceutical-research-on-international-space-station 2025-03-25T16:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasa-awards-redwire-contract-for-advanced-pharmaceutical-research-on-international-space-station 2025-03-25T16:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/merck-licenses-oral-lipoprotein-a-inhibitor-hrs-5346-from-hengrui-pharma-in-1-97-billion-deal 2025-03-25T16:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-licenses-oral-lipoprotein-a-inhibitor-hrs-5346-from-hengrui-pharma-in-1-97-billion-deal 2025-03-25T16:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/splash-clinical-and-c2n-diagnostics-partner-to-revolutionize-alzheimer-s-trial-recruitment-with-blood-based-biomarkers 2025-03-25T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splash-clinical-and-c2n-diagnostics-partner-to-revolutionize-alzheimer-s-trial-recruitment-with-blood-based-biomarkers 2025-03-25T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/veracyte-s-whole-genome-sequencing-mrd-test-shows-superior-accuracy-for-bladder-cancer-detection 2025-03-25T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veracyte-s-whole-genome-sequencing-mrd-test-shows-superior-accuracy-for-bladder-cancer-detection 2025-03-25T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-biosciences-partners-with-verdi-solutions-to-develop-ai-guided-cancer-vaccines 2025-03-25T15:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anixa-biosciences-partners-with-verdi-solutions-to-develop-ai-guided-cancer-vaccines 2025-03-25T15:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-qidp-designation-to-vast-therapeutics-alx1-for-pseudomonas-infections-in-bronchiectasis 2025-03-25T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-qidp-designation-to-vast-therapeutics-alx1-for-pseudomonas-infections-in-bronchiectasis 2025-03-25T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-s-novel-anti-il1rap-antibody-drug-conjugate-shows-promising-preclinical-efficacy-against-cancer 2025-03-25T13:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-s-novel-anti-il1rap-antibody-drug-conjugate-shows-promising-preclinical-efficacy-against-cancer 2025-03-25T13:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-signals-potential-traditional-approval-pathway-for-genelux-s-olvi-vec-in-platinum-resistant-ovarian-cancer 2025-03-25T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-signals-potential-traditional-approval-pathway-for-genelux-s-olvi-vec-in-platinum-resistant-ovarian-cancer 2025-03-25T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-to-present-comprehensive-kerendia-clinical-data-at-major-cardiology-and-nephrology-conferences 2025-03-25T13:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-to-present-comprehensive-kerendia-clinical-data-at-major-cardiology-and-nephrology-conferences 2025-03-25T13:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/enable-injections-secures-ce-mark-approval-for-enfuse-wearable-drug-delivery-platform-in-europe 2025-03-25T13:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enable-injections-secures-ce-mark-approval-for-enfuse-wearable-drug-delivery-platform-in-europe 2025-03-25T13:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/accent-therapeutics-to-showcase-novel-cancer-therapeutics-atx-559-and-atx-295-at-aacr-2025 2025-03-25T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accent-therapeutics-to-showcase-novel-cancer-therapeutics-atx-559-and-atx-295-at-aacr-2025 2025-03-25T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/berubicin-for-glioblastoma-cns-pharmaceuticals-reports-comparable-efficacy-to-standard-treatment-with-improved-safety-profile 2025-03-25T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/berubicin-for-glioblastoma-cns-pharmaceuticals-reports-comparable-efficacy-to-standard-treatment-with-improved-safety-profile 2025-03-25T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/hubble-therapeutics-secures-7-3m-series-a-funding-for-gene-therapy-targeting-rare-childhood-blindness 2025-03-25T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hubble-therapeutics-secures-7-3m-series-a-funding-for-gene-therapy-targeting-rare-childhood-blindness 2025-03-25T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/chemoid-assay-significantly-improves-response-rates-in-platinum-resistant-ovarian-cancer 2025-03-25T10:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chemoid-assay-significantly-improves-response-rates-in-platinum-resistant-ovarian-cancer 2025-03-25T10:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-moderna-lead-the-race-in-personalized-cancer-vaccine-development-with-promising-clinical-results 2025-03-25T10:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-moderna-lead-the-race-in-personalized-cancer-vaccine-development-with-promising-clinical-results 2025-03-25T10:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/edaravone-shows-promise-in-targeting-tdp-43-mislocalization-in-als-new-preclinical-research-reveals 2025-03-25T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edaravone-shows-promise-in-targeting-tdp-43-mislocalization-in-als-new-preclinical-research-reveals 2025-03-25T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/kyan-technologies-optim-ai-platform-demonstrates-85-clinical-concordance-across-multiple-cancer-types 2025-03-25T08:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyan-technologies-optim-ai-platform-demonstrates-85-clinical-concordance-across-multiple-cancer-types 2025-03-25T08:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/flerie-and-toleranzia-announce-merger-plan-to-take-toleranzia-private-in-eur12-5-million-deal 2025-03-25T08:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flerie-and-toleranzia-announce-merger-plan-to-take-toleranzia-private-in-eur12-5-million-deal 2025-03-25T08:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/needle-free-drug-delivery-devices-market-set-to-reach-5-billion-by-2035 2025-03-25T07:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/needle-free-drug-delivery-devices-market-set-to-reach-5-billion-by-2035 2025-03-25T07:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/hillstar-bio-raises-67m-series-a-to-advance-precision-immunotherapy-for-autoimmune-diseases 2025-03-25T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillstar-bio-raises-67m-series-a-to-advance-precision-immunotherapy-for-autoimmune-diseases 2025-03-25T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-pharma-to-present-phase-1b-2a-trial-of-nvg-291-for-spinal-cord-injury-at-upcoming-investor-event 2025-03-25T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nervgen-pharma-to-present-phase-1b-2a-trial-of-nvg-291-for-spinal-cord-injury-at-upcoming-investor-event 2025-03-25T05:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-and-valo-health-achieve-first-ai-driven-lupus-drug-candidate-using-logica-platform 2025-03-25T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-and-valo-health-achieve-first-ai-driven-lupus-drug-candidate-using-logica-platform 2025-03-25T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mr-linac-technology-advances-precision-radiation-therapy-across-multiple-cancer-types 2025-03-25T03:02:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mr-linac-technology-advances-precision-radiation-therapy-across-multiple-cancer-types 2025-03-25T03:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/nutrition-s-critical-role-in-cancer-care-from-prevention-to-survivorship 2025-03-25T03:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutrition-s-critical-role-in-cancer-care-from-prevention-to-survivorship 2025-03-25T03:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/ai-tool-successfully-predicts-prostate-cancer-treatment-outcomes-by-measuring-tumor-volume 2025-03-25T03:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-tool-successfully-predicts-prostate-cancer-treatment-outcomes-by-measuring-tumor-volume 2025-03-25T03:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/solve-fshd-partners-with-modalis-to-develop-crispr-based-epigenome-editing-therapy-for-muscular-dystrophy 2025-03-25T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solve-fshd-partners-with-modalis-to-develop-crispr-based-epigenome-editing-therapy-for-muscular-dystrophy 2025-03-25T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipoprotein-a-the-overlooked-cardiovascular-risk-factor-gaining-clinical-recognition 2025-03-25T02:35:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipoprotein-a-the-overlooked-cardiovascular-risk-factor-gaining-clinical-recognition 2025-03-25T02:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/neurosafe-technique-shows-significant-improvement-in-erectile-function-after-prostate-cancer-surgery 2025-03-25T02:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosafe-technique-shows-significant-improvement-in-erectile-function-after-prostate-cancer-surgery 2025-03-25T02:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-continues-expansion-with-nearly-300-new-stock-option-grants-to-support-til-therapy-development 2025-03-25T02:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-continues-expansion-with-nearly-300-new-stock-option-grants-to-support-til-therapy-development 2025-03-25T02:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-completes-phase-1-trial-of-ot-101-il-2-combination-for-advanced-solid-tumors 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncotelic-therapeutics-completes-phase-1-trial-of-ot-101-il-2-combination-for-advanced-solid-tumors 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/urolift-system-demonstrates-superior-patient-outcomes-in-head-to-head-bph-treatment-trials 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urolift-system-demonstrates-superior-patient-outcomes-in-head-to-head-bph-treatment-trials 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approval-of-humacyte-s-artificial-blood-vessel-faces-petition-for-revocation-amid-safety-concerns 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approval-of-humacyte-s-artificial-blood-vessel-faces-petition-for-revocation-amid-safety-concerns 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-nmpa-clears-phase-2-trial-of-first-in-class-sialidase-enzyme-therapy-for-autoimmune-kidney-disease 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-nmpa-clears-phase-2-trial-of-first-in-class-sialidase-enzyme-therapy-for-autoimmune-kidney-disease 2025-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/early-rituximab-treatment-shows-significant-benefits-for-advanced-stage-low-tumor-burden-follicular-lymphoma 2025-03-24T22:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-rituximab-treatment-shows-significant-benefits-for-advanced-stage-low-tumor-burden-follicular-lymphoma 2025-03-24T22:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-tenon-medical-s-catamaran-system-indication-for-thoracolumbar-fusion-augmentation 2025-03-24T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-tenon-medical-s-catamaran-system-indication-for-thoracolumbar-fusion-augmentation 2025-03-24T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/opm-101-enters-phase-1b-2a-trial-to-combat-melanoma-resistance-to-immunotherapy 2025-03-24T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opm-101-enters-phase-1b-2a-trial-to-combat-melanoma-resistance-to-immunotherapy 2025-03-24T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/anuncia-medical-s-reflow-evd-receives-fda-breakthrough-device-designation-for-intracranial-pressure-management 2025-03-24T19:36:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anuncia-medical-s-reflow-evd-receives-fda-breakthrough-device-designation-for-intracranial-pressure-management 2025-03-24T19:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-dawes-redman-ctg-analysis-for-fetal-monitoring-in-the-us 2025-03-24T19:35:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-dawes-redman-ctg-analysis-for-fetal-monitoring-in-the-us 2025-03-24T19:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abbott-s-coronary-ivl-system-trial-for-treating-calcified-coronary-artery-disease 2025-03-24T19:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-abbott-s-coronary-ivl-system-trial-for-treating-calcified-coronary-artery-disease 2025-03-24T19:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/experts-challenge-conventional-wisdom-on-drug-launch-pricing-evaluations 2025-03-24T19:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-challenge-conventional-wisdom-on-drug-launch-pricing-evaluations 2025-03-24T19:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/opthia-faces-1-billion-investor-obligation-following-sozinibercept-trial-failure-in-wetamd 2025-03-24T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opthia-faces-1-billion-investor-obligation-following-sozinibercept-trial-failure-in-wetamd 2025-03-24T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/spark-biomedical-completes-enrollment-in-two-pivotal-neurostimulation-trials-for-opioid-use-disorder-and-neonatal-withdrawal 2025-03-24T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spark-biomedical-completes-enrollment-in-two-pivotal-neurostimulation-trials-for-opioid-use-disorder-and-neonatal-withdrawal 2025-03-24T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/closed-loop-medicine-secures-us-patents-for-ai-powered-precision-dosing-in-glp-1-and-doac-therapies 2025-03-24T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/closed-loop-medicine-secures-us-patents-for-ai-powered-precision-dosing-in-glp-1-and-doac-therapies 2025-03-24T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/miebo-shows-rapid-relief-for-dry-eye-disease-within-minutes-of-first-use-phase-4-study-reveals 2025-03-24T16:36:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miebo-shows-rapid-relief-for-dry-eye-disease-within-minutes-of-first-use-phase-4-study-reveals 2025-03-24T16:36:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aligns-with-enabled-therapeutics-on-cpt-021-novel-targeted-therapy-for-alzheimer-s-disease 2025-03-24T16:36:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aligns-with-enabled-therapeutics-on-cpt-021-novel-targeted-therapy-for-alzheimer-s-disease 2025-03-24T16:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-sungen-biomedical-s-novel-antibody-for-acute-myocardial-infarction 2025-03-24T16:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-sungen-biomedical-s-novel-antibody-for-acute-myocardial-infarction 2025-03-24T16:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-s-xcelligence-technology-plays-critical-role-in-fda-approval-of-autolus-car-t-therapy 2025-03-24T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilent-s-xcelligence-technology-plays-critical-role-in-fda-approval-of-autolus-car-t-therapy 2025-03-24T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/secretome-therapeutics-initiates-phase-1-trial-of-novel-cell-therapy-stm-01-for-heart-failure 2025-03-24T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secretome-therapeutics-initiates-phase-1-trial-of-novel-cell-therapy-stm-01-for-heart-failure 2025-03-24T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/privo-technologies-launches-benevet-oncology-to-bring-human-cancer-treatment-innovations-to-veterinary-medicine 2025-03-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/privo-technologies-launches-benevet-oncology-to-bring-human-cancer-treatment-innovations-to-veterinary-medicine 2025-03-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/tempero-bio-secures-70m-series-b-to-advance-novel-addiction-treatment-through-phase-2-trials 2025-03-24T16:35:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempero-bio-secures-70m-series-b-to-advance-novel-addiction-treatment-through-phase-2-trials 2025-03-24T16:35:17+00:00 hourly 0.9 https://trial.medpath.com/news/aquablation-therapy-shows-comparable-efficacy-to-laser-enucleation-with-better-sexual-function-preservation-in-bph-treatment 2025-03-24T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquablation-therapy-shows-comparable-efficacy-to-laser-enucleation-with-better-sexual-function-preservation-in-bph-treatment 2025-03-24T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/phasev-unveils-ai-powered-platform-to-revolutionize-clinical-trial-design-and-analysis 2025-03-24T16:35:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phasev-unveils-ai-powered-platform-to-revolutionize-clinical-trial-design-and-analysis 2025-03-24T16:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-to-pursue-expanded-access-for-ht-001-to-treat-egfr-inhibitor-related-skin-toxicities 2025-03-24T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-to-pursue-expanded-access-for-ht-001-to-treat-egfr-inhibitor-related-skin-toxicities 2025-03-24T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-launches-fda-ema-approved-phase-3-trial-for-oral-psoriasis-drug-piclidenoson 2025-03-24T13:38:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-launches-fda-ema-approved-phase-3-trial-for-oral-psoriasis-drug-piclidenoson 2025-03-24T13:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/mit-develops-revolutionary-injectable-drug-depot-system-for-long-term-medication-delivery 2025-03-24T13:37:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-develops-revolutionary-injectable-drug-depot-system-for-long-term-medication-delivery 2025-03-24T13:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/powerful-medical-s-ai-driven-ecg-model-for-stemi-detection-receives-fda-breakthrough-designation 2025-03-24T13:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/powerful-medical-s-ai-driven-ecg-model-for-stemi-detection-receives-fda-breakthrough-designation 2025-03-24T13:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/mira-pharmaceuticals-to-acquire-skny-pharmaceuticals-expanding-into-200-billion-weight-loss-and-smoking-cessation-markets 2025-03-24T13:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mira-pharmaceuticals-to-acquire-skny-pharmaceuticals-expanding-into-200-billion-weight-loss-and-smoking-cessation-markets 2025-03-24T13:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/augustine-therapeutics-secures-eur78-million-to-advance-hdac6-inhibitor-for-charcot-marie-tooth-disease 2025-03-24T10:39:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/augustine-therapeutics-secures-eur78-million-to-advance-hdac6-inhibitor-for-charcot-marie-tooth-disease 2025-03-24T10:39:22+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-reports-promising-results-bio101-and-glp-1-combination-restores-muscle-strength-in-obesity 2025-03-24T10:39:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biophytis-reports-promising-results-bio101-and-glp-1-combination-restores-muscle-strength-in-obesity 2025-03-24T10:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/cizzle-biotechnology-expands-global-reach-for-early-lung-cancer-detection-test 2025-03-24T10:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cizzle-biotechnology-expands-global-reach-for-early-lung-cancer-detection-test 2025-03-24T10:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-iron-based-nanoparticles-could-revolutionize-triple-negative-breast-cancer-treatment 2025-03-24T10:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-iron-based-nanoparticles-could-revolutionize-triple-negative-breast-cancer-treatment 2025-03-24T10:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-pharma-secures-fda-approval-for-norepinephrine-bitartrate-injection-for-acute-hypotension 2025-03-24T10:38:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-pharma-secures-fda-approval-for-norepinephrine-bitartrate-injection-for-acute-hypotension 2025-03-24T10:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-streamlines-drug-registration-process-with-new-consultation-services 2025-03-24T10:38:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-streamlines-drug-registration-process-with-new-consultation-services 2025-03-24T10:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-cas9-market-set-to-surge-over-25-therapies-in-clinical-trials-expected-to-launch-within-5-7-years 2025-03-24T10:38:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-cas9-market-set-to-surge-over-25-therapies-in-clinical-trials-expected-to-launch-within-5-7-years 2025-03-24T10:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-launches-groundbreaking-hiv-cure-trial-in-south-africa-focusing-on-women 2025-03-24T10:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-launches-groundbreaking-hiv-cure-trial-in-south-africa-focusing-on-women 2025-03-24T10:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-reports-breakthrough-in-oral-delivery-of-tnf-a-inhibitor-for-inflammatory-diseases 2025-03-24T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tharimmune-reports-breakthrough-in-oral-delivery-of-tnf-a-inhibitor-for-inflammatory-diseases 2025-03-24T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-s-ak0901-completes-phase-iii-trial-for-adhd-in-china-showing-significant-efficacy 2025-03-24T04:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-s-ak0901-completes-phase-iii-trial-for-adhd-in-china-showing-significant-efficacy 2025-03-24T04:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-secures-10-million-funding-to-advance-rna-cancer-therapy-clinical-trials 2025-03-24T04:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-secures-10-million-funding-to-advance-rna-cancer-therapy-clinical-trials 2025-03-24T04:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/clover-advances-rsv-vaccine-program-with-fda-clearance-for-revaccination-trial 2025-03-24T04:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clover-advances-rsv-vaccine-program-with-fda-clearance-for-revaccination-trial 2025-03-24T04:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-vs-sglt2-inhibitors-comparative-cardiovascular-benefits-in-diabetes-management 2025-03-24T03:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-vs-sglt2-inhibitors-comparative-cardiovascular-benefits-in-diabetes-management 2025-03-24T03:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/nih-researchers-develop-eye-drops-that-could-slow-progression-of-retinitis-pigmentosa 2025-03-24T01:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-researchers-develop-eye-drops-that-could-slow-progression-of-retinitis-pigmentosa 2025-03-24T01:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-everest-medicines-ind-application-for-novel-mrna-cancer-vaccine-evm14 2025-03-24T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-everest-medicines-ind-application-for-novel-mrna-cancer-vaccine-evm14 2025-03-24T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-begins-phase-3-trial-of-novel-her2-adc-for-platinum-resistant-ovarian-cancer 2025-03-24T01:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-begins-phase-3-trial-of-novel-her2-adc-for-platinum-resistant-ovarian-cancer 2025-03-24T01:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-advances-in-head-and-neck-cancer-treatment-over-100-drugs-in-development-for-2025 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-advances-in-head-and-neck-cancer-treatment-over-100-drugs-in-development-for-2025 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/carbogen-amcis-achieves-gmp-certification-for-french-sterile-drug-manufacturing-facility 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carbogen-amcis-achieves-gmp-certification-for-french-sterile-drug-manufacturing-facility 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tim-3-decoy-enhances-car-t-cell-therapy-efficacy-in-b-cell-acute-lymphoblastic-leukemia 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tim-3-decoy-enhances-car-t-cell-therapy-efficacy-in-b-cell-acute-lymphoblastic-leukemia 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-prequalifies-first-maternal-rsv-vaccine-and-issues-global-immunization-recommendations 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-prequalifies-first-maternal-rsv-vaccine-and-issues-global-immunization-recommendations 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/coherus-reports-promising-phase-1-data-for-chs-114-in-head-and-neck-cancer-showing-potential-to-overcome-pd-1-resistance 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coherus-reports-promising-phase-1-data-for-chs-114-in-head-and-neck-cancer-showing-potential-to-overcome-pd-1-resistance 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/b-cell-lymphoma-pipeline-expands-with-300-therapies-in-development-for-2025 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-cell-lymphoma-pipeline-expands-with-300-therapies-in-development-for-2025 2025-03-24T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-rejects-phase-iii-trial-waivers-for-resmetirom-in-india-approves-bioequivalence-studies 2025-03-23T22:38:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-rejects-phase-iii-trial-waivers-for-resmetirom-in-india-approves-bioequivalence-studies 2025-03-23T22:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/organ-sparing-tmli-with-post-transplant-cyclophosphamide-shows-promising-results-for-aml-transplant-patients 2025-03-23T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organ-sparing-tmli-with-post-transplant-cyclophosphamide-shows-promising-results-for-aml-transplant-patients 2025-03-23T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-vitamin-d-delays-ms-progression-by-over-200-days-in-landmark-clinical-trial 2025-03-23T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-vitamin-d-delays-ms-progression-by-over-200-days-in-landmark-clinical-trial 2025-03-23T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-humanized-antibody-vx-01-shows-promise-against-deadly-mucormycosis 2025-03-23T15:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-humanized-antibody-vx-01-shows-promise-against-deadly-mucormycosis 2025-03-23T15:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/recombinant-zoster-vaccine-shows-strong-efficacy-and-safety-profile-in-rheumatoid-arthritis-patients 2025-03-23T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recombinant-zoster-vaccine-shows-strong-efficacy-and-safety-profile-in-rheumatoid-arthritis-patients 2025-03-23T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/rosemary-derived-compound-shows-promise-as-potential-alzheimer-s-treatment-in-preclinical-study 2025-03-23T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rosemary-derived-compound-shows-promise-as-potential-alzheimer-s-treatment-in-preclinical-study 2025-03-23T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/golidocitinib-plus-pd-1-antibodies-shows-promise-in-nsclc-patients-after-anti-pd-1-therapy-failure 2025-03-23T07:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/golidocitinib-plus-pd-1-antibodies-shows-promise-in-nsclc-patients-after-anti-pd-1-therapy-failure 2025-03-23T07:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-files-trade-secret-lawsuit-against-genmab-over-adc-technology-in-cancer-drug-development 2025-03-23T02:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-files-trade-secret-lawsuit-against-genmab-over-adc-technology-in-cancer-drug-development 2025-03-23T02:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-in-gastric-cancer-moving-to-earlier-disease-stages-and-optimizing-combination-approaches 2025-03-23T02:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-in-gastric-cancer-moving-to-earlier-disease-stages-and-optimizing-combination-approaches 2025-03-23T02:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/abpi-nihr-and-amrc-join-forces-to-advance-patient-involvement-in-pharmaceutical-research 2025-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abpi-nihr-and-amrc-join-forces-to-advance-patient-involvement-in-pharmaceutical-research 2025-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mit-researchers-develop-antibody-painting-technology-to-enhance-glp-1-drug-delivery 2025-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-researchers-develop-antibody-painting-technology-to-enhance-glp-1-drug-delivery 2025-03-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wistar-institute-scientists-develop-next-generation-dna-lnp-vaccine-technology-with-enhanced-immune-response 2025-03-22T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wistar-institute-scientists-develop-next-generation-dna-lnp-vaccine-technology-with-enhanced-immune-response 2025-03-22T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/evidence-based-survivorship-care-programs-enhance-quality-of-life-for-cancer-patients 2025-03-22T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evidence-based-survivorship-care-programs-enhance-quality-of-life-for-cancer-patients 2025-03-22T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/kalaris-and-allovir-complete-merger-to-advance-novel-anti-vegf-therapy-for-retinal-diseases 2025-03-22T13:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalaris-and-allovir-complete-merger-to-advance-novel-anti-vegf-therapy-for-retinal-diseases 2025-03-22T13:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/accelerate-diagnostics-seeks-fda-clearance-for-rapid-antimicrobial-susceptibility-testing-system 2025-03-22T13:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accelerate-diagnostics-seeks-fda-clearance-for-rapid-antimicrobial-susceptibility-testing-system 2025-03-22T13:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/elahere-demonstrates-significant-survival-benefit-in-phase-iii-mirasol-trial-for-platinum-resistant-ovarian-cancer 2025-03-22T04:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elahere-demonstrates-significant-survival-benefit-in-phase-iii-mirasol-trial-for-platinum-resistant-ovarian-cancer 2025-03-22T04:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-and-cipla-form-strategic-partnership-for-app13007-commercialization-across-11-countries 2025-03-22T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-and-cipla-form-strategic-partnership-for-app13007-commercialization-across-11-countries 2025-03-22T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-reports-promising-interim-results-for-alzheimer-s-agitation-therapy 2025-03-22T01:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-reports-promising-interim-results-for-alzheimer-s-agitation-therapy 2025-03-22T01:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/inhaled-insulin-shows-promising-results-in-type-1-diabetes-management-over-30-weeks 2025-03-21T22:35:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhaled-insulin-shows-promising-results-in-type-1-diabetes-management-over-30-weeks 2025-03-21T22:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/sugar-based-gel-shows-promise-as-natural-hair-loss-treatment-in-preclinical-study 2025-03-21T22:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sugar-based-gel-shows-promise-as-natural-hair-loss-treatment-in-preclinical-study 2025-03-21T22:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-alnylam-s-amvuttra-for-attr-cardiomyopathy-sending-stock-soaring 2025-03-21T22:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-alnylam-s-amvuttra-for-attr-cardiomyopathy-sending-stock-soaring 2025-03-21T22:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-completes-exit-from-haleon-with-3-3-billion-stake-sale 2025-03-21T19:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-completes-exit-from-haleon-with-3-3-billion-stake-sale 2025-03-21T19:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/hypera-to-launch-generic-semaglutide-in-brazil-ahead-of-2026-patent-expiration 2025-03-21T19:35:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypera-to-launch-generic-semaglutide-in-brazil-ahead-of-2026-patent-expiration 2025-03-21T19:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/pln-101095-combined-with-pembrolizumab-shows-promising-activity-in-ici-refractory-solid-tumors 2025-03-21T19:35:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pln-101095-combined-with-pembrolizumab-shows-promising-activity-in-ici-refractory-solid-tumors 2025-03-21T19:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tremfya-for-crohn-s-disease-and-fabhalta-for-rare-kidney-disease-amid-major-pharma-acquisitions 2025-03-21T19:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tremfya-for-crohn-s-disease-and-fabhalta-for-rare-kidney-disease-amid-major-pharma-acquisitions 2025-03-21T19:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/isofol-medical-advances-arfolitixorin-development-with-new-phase-ib-ii-trial-for-metastatic-colorectal-cancer 2025-03-21T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isofol-medical-advances-arfolitixorin-development-with-new-phase-ib-ii-trial-for-metastatic-colorectal-cancer 2025-03-21T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-commits-55-billion-to-expand-u-s-manufacturing-and-r-d-capabilities 2025-03-21T18:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-commits-55-billion-to-expand-u-s-manufacturing-and-r-d-capabilities 2025-03-21T18:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-aphranel-magiccrystal-caha-filler-receives-global-regulatory-approvals-setting-new-standards-in-regenerative-aesthetics 2025-03-21T17:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-aphranel-magiccrystal-caha-filler-receives-global-regulatory-approvals-setting-new-standards-in-regenerative-aesthetics 2025-03-21T17:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-at-home-urine-test-accurately-detects-aggressive-prostate-cancer-reducing-need-for-invasive-procedures 2025-03-21T17:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-at-home-urine-test-accurately-detects-aggressive-prostate-cancer-reducing-need-for-invasive-procedures 2025-03-21T17:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-grants-conditional-approval-to-tazemetostat-for-ezh2-mutant-follicular-lymphoma 2025-03-21T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-grants-conditional-approval-to-tazemetostat-for-ezh2-mutant-follicular-lymphoma 2025-03-21T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-second-rejection-for-rivoceranib-camrelizumab-combination-in-unresectable-liver-cancer 2025-03-21T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-second-rejection-for-rivoceranib-camrelizumab-combination-in-unresectable-liver-cancer 2025-03-21T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-illuminate-trial-tilsotolimod-plus-ipilimumab-fails-to-improve-outcomes-in-advanced-refractory-melanoma 2025-03-21T16:37:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-illuminate-trial-tilsotolimod-plus-ipilimumab-fails-to-improve-outcomes-in-advanced-refractory-melanoma 2025-03-21T16:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/china-grants-conditional-approval-for-tazverik-to-treat-relapsed-or-refractory-follicular-lymphoma 2025-03-21T16:37:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-grants-conditional-approval-for-tazverik-to-treat-relapsed-or-refractory-follicular-lymphoma 2025-03-21T16:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/hlb-group-to-resubmit-riboceranib-for-fda-approval-following-second-rejection 2025-03-21T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hlb-group-to-resubmit-riboceranib-for-fda-approval-following-second-rejection 2025-03-21T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-telix-pharmaceuticals-novel-prostate-cancer-imaging-agent 2025-03-21T16:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-telix-pharmaceuticals-novel-prostate-cancer-imaging-agent 2025-03-21T16:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-advances-zaltenibart-phase-3-trials-for-pnh-with-potential-superiority-over-current-treatments 2025-03-21T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-advances-zaltenibart-phase-3-trials-for-pnh-with-potential-superiority-over-current-treatments 2025-03-21T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/yaqrit-secures-ps2-2-million-nihr-grant-for-pivotal-dialive-liver-support-device-trials 2025-03-21T16:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yaqrit-secures-ps2-2-million-nihr-grant-for-pivotal-dialive-liver-support-device-trials 2025-03-21T16:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-s-personalized-cancer-vaccine-pgv001-shows-promise-across-multiple-tumor-types-in-phase-1-trial 2025-03-21T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-s-personalized-cancer-vaccine-pgv001-shows-promise-across-multiple-tumor-types-in-phase-1-trial 2025-03-21T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-reveals-critical-insights-into-clinical-stage-pharma-partnerships-from-2020-2025 2025-03-21T13:35:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-reveals-critical-insights-into-clinical-stage-pharma-partnerships-from-2020-2025 2025-03-21T13:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-invests-2-5-billion-in-beijing-to-establish-sixth-global-r-d-center 2025-03-21T10:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-invests-2-5-billion-in-beijing-to-establish-sixth-global-r-d-center 2025-03-21T10:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/angle-s-parsortix-system-shows-promise-in-real-time-her2-status-monitoring-for-breast-cancer-patients 2025-03-21T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angle-s-parsortix-system-shows-promise-in-real-time-her2-status-monitoring-for-breast-cancer-patients 2025-03-21T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-bevacizumab-combination-shows-promising-survival-outcomes-for-melanoma-brain-metastases 2025-03-21T10:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pembrolizumab-bevacizumab-combination-shows-promising-survival-outcomes-for-melanoma-brain-metastases 2025-03-21T10:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/feinstein-institutes-pioneers-precision-vagus-nerve-stimulation-with-3m-nih-grant 2025-03-21T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/feinstein-institutes-pioneers-precision-vagus-nerve-stimulation-with-3m-nih-grant 2025-03-21T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-factors-influencing-immune-checkpoint-inhibitor-efficacy-in-metastatic-colorectal-cancer 2025-03-21T04:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-factors-influencing-immune-checkpoint-inhibitor-efficacy-in-metastatic-colorectal-cancer 2025-03-21T04:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-reports-65-growth-in-oncology-products-revenue-achieves-profitability-in-2024 2025-03-21T03:02:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-reports-65-growth-in-oncology-products-revenue-achieves-profitability-in-2024 2025-03-21T03:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/autolus-therapeutics-advances-obe-cel-into-pivotal-phase-2-trial-for-systemic-lupus-erythematosus 2025-03-21T02:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autolus-therapeutics-advances-obe-cel-into-pivotal-phase-2-trial-for-systemic-lupus-erythematosus 2025-03-21T02:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ind-clearance-to-triastek-s-3d-printed-once-daily-anticoagulant-t20g 2025-03-21T02:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ind-clearance-to-triastek-s-3d-printed-once-daily-anticoagulant-t20g 2025-03-21T02:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-reports-promising-clinical-progress-with-hdp-101-in-multiple-myeloma-and-advances-hdp-102-into-clinical-trials 2025-03-21T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-reports-promising-clinical-progress-with-hdp-101-in-multiple-myeloma-and-advances-hdp-102-into-clinical-trials 2025-03-21T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-hemorrhage-treatment-market-expected-to-grow-significantly-by-2032-as-ai-solutions-gain-fda-approval 2025-03-21T01:35:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-hemorrhage-treatment-market-expected-to-grow-significantly-by-2032-as-ai-solutions-gain-fda-approval 2025-03-21T01:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-alnylam-s-amvuttra-for-attr-cm-expanding-treatment-options-for-cardiomyopathy-patients 2025-03-21T01:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-alnylam-s-amvuttra-for-attr-cm-expanding-treatment-options-for-cardiomyopathy-patients 2025-03-21T01:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-invests-75-million-in-india-s-first-integrated-cell-and-gene-therapy-facility 2025-03-21T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-biotech-invests-75-million-in-india-s-first-integrated-cell-and-gene-therapy-facility 2025-03-21T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/london-biotechnology-show-2025-returns-with-expanded-platform-for-industry-innovation-and-collaboration 2025-03-21T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/london-biotechnology-show-2025-returns-with-expanded-platform-for-industry-innovation-and-collaboration 2025-03-21T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-infant-successfully-treated-with-novel-gene-therapy-for-rare-metabolic-disorder 2025-03-21T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-infant-successfully-treated-with-novel-gene-therapy-for-rare-metabolic-disorder 2025-03-21T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-identifies-key-biomarkers-for-predicting-gastric-cancer-immunotherapy-response 2025-03-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-review-identifies-key-biomarkers-for-predicting-gastric-cancer-immunotherapy-response 2025-03-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-moonrise-1-trial-evaluates-tar-210-erdafitinib-system-for-bladder-cancer 2025-03-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-moonrise-1-trial-evaluates-tar-210-erdafitinib-system-for-bladder-cancer 2025-03-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/canada-expands-access-to-rare-disease-medications-through-provincial-agreements 2025-03-20T23:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-expands-access-to-rare-disease-medications-through-provincial-agreements 2025-03-20T23:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-backs-alnylam-s-onpattro-for-attr-cardiomyopathy-despite-efficacy-concerns 2025-03-20T23:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-backs-alnylam-s-onpattro-for-attr-cardiomyopathy-despite-efficacy-concerns 2025-03-20T23:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/curetopia-raises-1-77m-on-solana-blockchain-to-develop-first-treatment-for-aars2-deficiency 2025-03-20T22:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curetopia-raises-1-77m-on-solana-blockchain-to-develop-first-treatment-for-aars2-deficiency 2025-03-20T22:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/uva-health-launches-two-national-clinical-trials-to-combat-long-covid 2025-03-20T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-health-launches-two-national-clinical-trials-to-combat-long-covid 2025-03-20T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/olema-oncology-advances-pivotal-phase-3-trials-for-palazestrant-in-metastatic-breast-cancer 2025-03-20T22:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olema-oncology-advances-pivotal-phase-3-trials-for-palazestrant-in-metastatic-breast-cancer 2025-03-20T22:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/bd-initiates-pivotal-stance-trial-testing-galaflex-lite-scaffold-for-reducing-capsular-contracture-in-breast-implant-revision-surgery 2025-03-20T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-initiates-pivotal-stance-trial-testing-galaflex-lite-scaffold-for-reducing-capsular-contracture-in-breast-implant-revision-surgery 2025-03-20T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/darzalex-dominates-multiple-myeloma-market-with-11-6-billion-in-global-sales 2025-03-20T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/darzalex-dominates-multiple-myeloma-market-with-11-6-billion-in-global-sales 2025-03-20T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-patent-term-extensions-for-reissue-patents-based-on-original-patent-issue-date 2025-03-20T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-rules-patent-term-extensions-for-reissue-patents-based-on-original-patent-issue-date 2025-03-20T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/wugen-initiates-pivotal-trial-of-novel-off-the-shelf-car-t-therapy-for-rare-blood-cancers 2025-03-20T19:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wugen-initiates-pivotal-trial-of-novel-off-the-shelf-car-t-therapy-for-rare-blood-cancers 2025-03-20T19:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/eyenovia-and-betaliq-plan-reverse-merger-to-create-innovative-ophthalmic-technology-company 2025-03-20T19:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyenovia-and-betaliq-plan-reverse-merger-to-create-innovative-ophthalmic-technology-company 2025-03-20T19:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/windtree-therapeutics-partners-with-evofem-to-manufacture-fda-approved-contraceptive-phexxi 2025-03-20T19:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windtree-therapeutics-partners-with-evofem-to-manufacture-fda-approved-contraceptive-phexxi 2025-03-20T19:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-initiates-pharmacokinetic-studies-to-resolve-fda-clinical-hold-on-als-drug-nuz-001 2025-03-20T17:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurizon-initiates-pharmacokinetic-studies-to-resolve-fda-clinical-hold-on-als-drug-nuz-001 2025-03-20T17:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/clostrabio-secures-invent-illinois-funding-appoints-new-cso-and-prepares-for-microbiome-therapeutic-launch 2025-03-20T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clostrabio-secures-invent-illinois-funding-appoints-new-cso-and-prepares-for-microbiome-therapeutic-launch 2025-03-20T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/liscure-biosciences-secures-first-ever-regulatory-approval-for-hair-health-probiotic-ingredient 2025-03-20T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liscure-biosciences-secures-first-ever-regulatory-approval-for-hair-health-probiotic-ingredient 2025-03-20T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-to-unveil-novel-e2-based-targeted-protein-degradation-platform-at-european-summit 2025-03-20T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bpgbio-to-unveil-novel-e2-based-targeted-protein-degradation-platform-at-european-summit 2025-03-20T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/kiffik-biomedical-and-rubix-ls-join-forces-to-develop-novel-non-invasive-colorectal-cancer-test 2025-03-20T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiffik-biomedical-and-rubix-ls-join-forces-to-develop-novel-non-invasive-colorectal-cancer-test 2025-03-20T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-initiates-phase-1b-2a-trial-of-pocenbrodib-for-metastatic-castration-resistant-prostate-cancer 2025-03-20T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathos-ai-initiates-phase-1b-2a-trial-of-pocenbrodib-for-metastatic-castration-resistant-prostate-cancer 2025-03-20T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/icon-becomes-first-major-cro-to-fully-implement-medidata-s-ai-powered-clinical-data-studio 2025-03-20T16:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icon-becomes-first-major-cro-to-fully-implement-medidata-s-ai-powered-clinical-data-studio 2025-03-20T16:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/esperion-advances-bempedoic-acid-to-phase-3-trials-for-pediatric-familial-hypercholesterolemia 2025-03-20T13:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperion-advances-bempedoic-acid-to-phase-3-trials-for-pediatric-familial-hypercholesterolemia 2025-03-20T13:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/dsmb-recommends-continuation-of-briacell-s-phase-3-trial-for-metastatic-breast-cancer-immunotherapy 2025-03-20T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dsmb-recommends-continuation-of-briacell-s-phase-3-trial-for-metastatic-breast-cancer-immunotherapy 2025-03-20T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/ionctura-initiates-phase-ii-ocule-01-trial-of-roginolisib-for-metastatic-uveal-melanoma 2025-03-20T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionctura-initiates-phase-ii-ocule-01-trial-of-roginolisib-for-metastatic-uveal-melanoma 2025-03-20T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/sibel-health-secures-30-million-series-c-funding-and-new-fda-clearance-for-interoperable-monitoring-platform 2025-03-20T13:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sibel-health-secures-30-million-series-c-funding-and-new-fda-clearance-for-interoperable-monitoring-platform 2025-03-20T13:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-second-manufacturing-site-for-contrave-bolstering-supply-chain-for-leading-oral-weight-loss-medication 2025-03-20T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-second-manufacturing-site-for-contrave-bolstering-supply-chain-for-leading-oral-weight-loss-medication 2025-03-20T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-and-nrg-oncology-partner-to-streamline-clinical-trial-data-management-with-ehr-to-edc-technology 2025-03-20T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-and-nrg-oncology-partner-to-streamline-clinical-trial-data-management-with-ehr-to-edc-technology 2025-03-20T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/intelligent-bio-solutions-secures-sixth-u-s-patent-for-fingerprint-drug-screening-technology 2025-03-20T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intelligent-bio-solutions-secures-sixth-u-s-patent-for-fingerprint-drug-screening-technology 2025-03-20T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-voxzogo-shows-promising-results-in-reducing-tibial-bowing-in-children-with-achondroplasia 2025-03-20T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-voxzogo-shows-promising-results-in-reducing-tibial-bowing-in-children-with-achondroplasia 2025-03-20T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-reports-promising-early-results-for-gene-circuit-car-nk-cell-therapy-in-relapsed-refractory-aml 2025-03-20T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-reports-promising-early-results-for-gene-circuit-car-nk-cell-therapy-in-relapsed-refractory-aml 2025-03-20T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-awards-4-5-million-to-accelerate-vaccine-development-using-dyadic-s-c1-fungal-platform 2025-03-20T12:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-awards-4-5-million-to-accelerate-vaccine-development-using-dyadic-s-c1-fungal-platform 2025-03-20T12:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-sells-skyline-medical-assets-to-deroyal-industries-to-focus-on-ai-driven-cancer-drug-discovery 2025-03-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-sells-skyline-medical-assets-to-deroyal-industries-to-focus-on-ai-driven-cancer-drug-discovery 2025-03-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sionna-therapeutics-reports-positive-phase-1-results-for-novel-cystic-fibrosis-nbd1-stabilizers 2025-03-20T11:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sionna-therapeutics-reports-positive-phase-1-results-for-novel-cystic-fibrosis-nbd1-stabilizers 2025-03-20T11:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/pioneering-hiv-remission-trial-in-south-africa-shows-promise-for-drug-free-control 2025-03-20T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pioneering-hiv-remission-trial-in-south-africa-shows-promise-for-drug-free-control 2025-03-20T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-acquires-dren-bio-s-novel-b-cell-depleter-for-600-million-expanding-immunology-pipeline 2025-03-20T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-acquires-dren-bio-s-novel-b-cell-depleter-for-600-million-expanding-immunology-pipeline 2025-03-20T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/pharming-group-initiates-phase-ii-trial-of-leniolisib-for-cvid-with-immune-dysregulation 2025-03-20T10:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharming-group-initiates-phase-ii-trial-of-leniolisib-for-cvid-with-immune-dysregulation 2025-03-20T10:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/lupus-research-alliance-awards-4-5-million-to-pioneer-next-generation-cell-therapies-for-lupus 2025-03-20T08:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupus-research-alliance-awards-4-5-million-to-pioneer-next-generation-cell-therapies-for-lupus 2025-03-20T08:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-hikma-s-kloxxado-r-8-mg-nasal-spray-for-opioid-overdose-treatment 2025-03-20T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-hikma-s-kloxxado-r-8-mg-nasal-spray-for-opioid-overdose-treatment 2025-03-20T08:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/merigolix-shows-promise-in-multiple-indications-as-tiumbio-s-oral-gnrh-antagonist-advances-in-clinical-trials 2025-03-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merigolix-shows-promise-in-multiple-indications-as-tiumbio-s-oral-gnrh-antagonist-advances-in-clinical-trials 2025-03-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flatiron-health-breaks-new-ground-with-cross-border-patient-level-oncology-data-sharing 2025-03-20T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flatiron-health-breaks-new-ground-with-cross-border-patient-level-oncology-data-sharing 2025-03-20T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/bon-secures-32-million-deal-for-novel-postbiotic-blood-sugar-management-solution 2025-03-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bon-secures-32-million-deal-for-novel-postbiotic-blood-sugar-management-solution 2025-03-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-phospholipid-complex-boosts-cbd-bioavailability-for-epilepsy-and-ms-treatment 2025-03-20T04:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-phospholipid-complex-boosts-cbd-bioavailability-for-epilepsy-and-ms-treatment 2025-03-20T04:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-de-novo-clearance-to-nanosonics-coris-automated-endoscope-cleaning-system 2025-03-20T04:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-de-novo-clearance-to-nanosonics-coris-automated-endoscope-cleaning-system 2025-03-20T04:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-bioinvent-s-bi-1808-for-t-cell-lymphoma-treatment 2025-03-20T03:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-bioinvent-s-bi-1808-for-t-cell-lymphoma-treatment 2025-03-20T03:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/paratek-pharmaceuticals-acquires-optinose-for-330-million-to-expand-xhance-access-in-chronic-rhinosinusitis-market 2025-03-20T02:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paratek-pharmaceuticals-acquires-optinose-for-330-million-to-expand-xhance-access-in-chronic-rhinosinusitis-market 2025-03-20T02:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/savolitinib-plus-tagrisso-r-shows-56-response-rate-in-met-high-lung-cancer-hutchmed-reports 2025-03-20T01:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savolitinib-plus-tagrisso-r-shows-56-response-rate-in-met-high-lung-cancer-hutchmed-reports 2025-03-20T01:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-quibim-s-ai-powered-prostate-cancer-detection-tool-for-us-market 2025-03-20T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-quibim-s-ai-powered-prostate-cancer-detection-tool-for-us-market 2025-03-20T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/usda-approves-first-autologous-immunotherapy-for-canine-osteosarcoma 2025-03-20T01:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usda-approves-first-autologous-immunotherapy-for-canine-osteosarcoma 2025-03-20T01:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/ema-proposes-paradigm-shift-to-include-pregnant-and-breastfeeding-women-in-clinical-trials 2025-03-20T01:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-proposes-paradigm-shift-to-include-pregnant-and-breastfeeding-women-in-clinical-trials 2025-03-20T01:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-europe-s-complex-market-access-landscape-five-emerging-strategies-for-pharmaceutical-success 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigating-europe-s-complex-market-access-landscape-five-emerging-strategies-for-pharmaceutical-success 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/diagnexia-partners-with-artera-to-launch-ai-powered-prostate-cancer-test-in-uk 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagnexia-partners-with-artera-to-launch-ai-powered-prostate-cancer-test-in-uk 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-secures-nasdaq-listing-expands-brain-cancer-clinical-trials-to-india 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-secures-nasdaq-listing-expands-brain-cancer-clinical-trials-to-india 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-regains-global-control-of-imcivree-by-reacquiring-rights-in-china 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-regains-global-control-of-imcivree-by-reacquiring-rights-in-china 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amphista-therapeutics-advances-novel-brd9-degraders-using-proprietary-targeted-glue-technology 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amphista-therapeutics-advances-novel-brd9-degraders-using-proprietary-targeted-glue-technology 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verve-therapeutics-expands-base-editing-trial-for-cholesterol-treatment-into-us-following-fda-clearance 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verve-therapeutics-expands-base-editing-trial-for-cholesterol-treatment-into-us-following-fda-clearance 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/everhope-oncology-launches-with-10m-seed-funding-to-transform-cancer-care-in-india 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everhope-oncology-launches-with-10m-seed-funding-to-transform-cancer-care-in-india 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/keap1-gene-identified-as-key-driver-of-chemoresistance-in-small-cell-lung-cancer 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keap1-gene-identified-as-key-driver-of-chemoresistance-in-small-cell-lung-cancer 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-considers-eliminating-cdc-s-hiv-prevention-division 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-considers-eliminating-cdc-s-hiv-prevention-division 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sitryx-launches-phase-1-trial-of-novel-oral-pkm2-modulator-for-atopic-dermatitis 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sitryx-launches-phase-1-trial-of-novel-oral-pkm2-modulator-for-atopic-dermatitis 2025-03-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/setmelanotide-receives-orphan-drug-designation-in-japan-for-hypothalamic-obesity-treatment 2025-03-19T23:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/setmelanotide-receives-orphan-drug-designation-in-japan-for-hypothalamic-obesity-treatment 2025-03-19T23:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/evinova-s-remote-monitoring-technology-integrated-into-major-breast-cancer-platform-trial-to-detect-early-lung-complications 2025-03-19T23:02:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evinova-s-remote-monitoring-technology-integrated-into-major-breast-cancer-platform-trial-to-detect-early-lung-complications 2025-03-19T23:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/virogates-and-sobi-expand-collaboration-on-suparnostic-r-diagnostic-for-kineret-r-treatment 2025-03-19T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virogates-and-sobi-expand-collaboration-on-suparnostic-r-diagnostic-for-kineret-r-treatment 2025-03-19T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/first-pediatric-dopamine-hydrochloride-formulation-receives-mhra-approval-for-treating-hypotension-in-children 2025-03-19T22:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-pediatric-dopamine-hydrochloride-formulation-receives-mhra-approval-for-treating-hypotension-in-children 2025-03-19T22:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-ctx-offering-hope-to-patients-with-rare-genetic-disorder 2025-03-19T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-ctx-offering-hope-to-patients-with-rare-genetic-disorder 2025-03-19T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/lenz-therapeutics-advances-towards-august-2025-fda-decision-for-novel-presbyopia-eye-drop 2025-03-19T20:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenz-therapeutics-advances-towards-august-2025-fda-decision-for-novel-presbyopia-eye-drop 2025-03-19T20:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/uric-acid-shows-promise-as-novel-add-on-therapy-for-ischemic-stroke-in-nih-funded-study 2025-03-19T20:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uric-acid-shows-promise-as-novel-add-on-therapy-for-ischemic-stroke-in-nih-funded-study 2025-03-19T20:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-progress-over-25-new-therapies-in-development-for-metastatic-liver-cancer 2025-03-19T19:34:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-progress-over-25-new-therapies-in-development-for-metastatic-liver-cancer 2025-03-19T19:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-study-shows-aflibercept-treat-and-extend-regimen-maintains-vision-in-neovascular-amd-patients 2025-03-19T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-study-shows-aflibercept-treat-and-extend-regimen-maintains-vision-in-neovascular-amd-patients 2025-03-19T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-hlx22-for-gastric-cancer-treatment 2025-03-19T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-hlx22-for-gastric-cancer-treatment 2025-03-19T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/pomalidomide-based-combinations-show-promising-efficacy-in-relapsed-refractory-multiple-myeloma 2025-03-19T19:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pomalidomide-based-combinations-show-promising-efficacy-in-relapsed-refractory-multiple-myeloma 2025-03-19T19:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-aligns-with-signal12-on-phase-3-trial-design-for-novel-ocular-gvhd-therapy-pro-ocular 2025-03-19T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-aligns-with-signal12-on-phase-3-trial-design-for-novel-ocular-gvhd-therapy-pro-ocular 2025-03-19T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-england-denies-access-to-life-extending-prostate-cancer-treatments-despite-strong-clinical-evidence 2025-03-19T19:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-england-denies-access-to-life-extending-prostate-cancer-treatments-despite-strong-clinical-evidence 2025-03-19T19:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/informeddna-acquires-coriell-life-sciences-to-advance-pharmacogenomics-and-precision-medicine 2025-03-19T17:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/informeddna-acquires-coriell-life-sciences-to-advance-pharmacogenomics-and-precision-medicine 2025-03-19T17:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/google-deepmind-unveils-txgemma-open-ai-models-to-accelerate-drug-discovery 2025-03-19T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-deepmind-unveils-txgemma-open-ai-models-to-accelerate-drug-discovery 2025-03-19T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/immunovant-halts-regulatory-plans-for-rare-disease-drug-despite-phase-3-success 2025-03-19T16:35:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunovant-halts-regulatory-plans-for-rare-disease-drug-despite-phase-3-success 2025-03-19T16:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-invests-in-ampersand-biomedicines-65m-series-b-for-precision-drug-delivery-platform 2025-03-19T16:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-invests-in-ampersand-biomedicines-65m-series-b-for-precision-drug-delivery-platform 2025-03-19T16:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/servier-and-black-diamond-therapeutics-forge-780m-global-licensing-deal-for-novel-raf-ras-cancer-therapy 2025-03-19T16:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-and-black-diamond-therapeutics-forge-780m-global-licensing-deal-for-novel-raf-ras-cancer-therapy 2025-03-19T16:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/t45-labs-secures-oversubscribed-25m-fund-to-advance-cardiovascular-medical-devices 2025-03-19T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t45-labs-secures-oversubscribed-25m-fund-to-advance-cardiovascular-medical-devices 2025-03-19T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-launches-clinical-trial-testing-osteoporosis-drug-for-type-1-diabetes-treatment 2025-03-19T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-launches-clinical-trial-testing-osteoporosis-drug-for-type-1-diabetes-treatment 2025-03-19T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-advances-piclidenoson-to-phase-ii-trial-for-rare-lowe-syndrome-with-no-current-treatments 2025-03-19T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-advances-piclidenoson-to-phase-ii-trial-for-rare-lowe-syndrome-with-no-current-treatments 2025-03-19T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-biomerieux-s-vitek-compact-pro-system-to-combat-antimicrobial-resistance 2025-03-19T16:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-biomerieux-s-vitek-compact-pro-system-to-combat-antimicrobial-resistance 2025-03-19T16:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-s-novel-cancer-drug-ateganosine-receives-usan-approval-for-nsclc-treatment 2025-03-19T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-s-novel-cancer-drug-ateganosine-receives-usan-approval-for-nsclc-treatment 2025-03-19T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/abvc-biopharma-projects-19-million-revenue-from-global-licensing-deals-and-strategic-cdmo-acquisition 2025-03-19T16:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abvc-biopharma-projects-19-million-revenue-from-global-licensing-deals-and-strategic-cdmo-acquisition 2025-03-19T16:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-secures-50-million-through-public-offering-to-advance-kidney-disease-treatments 2025-03-19T16:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-therapeutics-secures-50-million-through-public-offering-to-advance-kidney-disease-treatments 2025-03-19T16:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-secures-100m-financing-to-advance-yutrepia-for-pulmonary-hypertension-treatment 2025-03-19T14:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-secures-100m-financing-to-advance-yutrepia-for-pulmonary-hypertension-treatment 2025-03-19T14:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-hengrui-hlb-liver-cancer-combination-therapy-for-second-time 2025-03-19T14:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-hengrui-hlb-liver-cancer-combination-therapy-for-second-time 2025-03-19T14:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/merck-to-present-phase-3-zenith-trial-results-for-winrevair-in-high-risk-pah-patients-at-acc-25 2025-03-19T13:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-to-present-phase-3-zenith-trial-results-for-winrevair-in-high-risk-pah-patients-at-acc-25 2025-03-19T13:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/immunovant-shifts-focus-to-next-gen-therapy-despite-positive-phase-iii-results-for-batoclimab-in-myasthenia-gravis 2025-03-19T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunovant-shifts-focus-to-next-gen-therapy-despite-positive-phase-iii-results-for-batoclimab-in-myasthenia-gravis 2025-03-19T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/primo-and-abx-partner-to-introduce-advanced-psma-targeting-radiotracer-for-prostate-cancer-diagnosis-in-taiwan 2025-03-19T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/primo-and-abx-partner-to-introduce-advanced-psma-targeting-radiotracer-for-prostate-cancer-diagnosis-in-taiwan 2025-03-19T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/vapendavir-shows-promise-in-phase-2-trial-for-rhinovirus-induced-copd-exacerbations 2025-03-19T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vapendavir-shows-promise-in-phase-2-trial-for-rhinovirus-induced-copd-exacerbations 2025-03-19T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-partners-to-develop-novel-intranasal-delivery-system-for-psychedelic-therapeutics 2025-03-19T10:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyrizon-partners-to-develop-novel-intranasal-delivery-system-for-psychedelic-therapeutics 2025-03-19T10:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-launches-phase-2a-trial-of-gamifant-for-interferon-gamma-driven-sepsis 2025-03-19T10:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-launches-phase-2a-trial-of-gamifant-for-interferon-gamma-driven-sepsis 2025-03-19T10:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/germany-adapts-amnog-framework-to-align-with-eu-hta-regulation-for-medicinal-products 2025-03-19T10:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/germany-adapts-amnog-framework-to-align-with-eu-hta-regulation-for-medicinal-products 2025-03-19T10:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-investigational-therapy-shows-promising-results-for-rare-mitochondrial-disease-tk2d 2025-03-19T10:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-investigational-therapy-shows-promising-results-for-rare-mitochondrial-disease-tk2d 2025-03-19T10:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/immunovia-s-next-generation-pancreatic-cancer-test-shows-77-detection-rate-in-early-stage-disease 2025-03-19T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunovia-s-next-generation-pancreatic-cancer-test-shows-77-detection-rate-in-early-stage-disease 2025-03-19T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/acrivon-therapeutics-to-showcase-ap3-platform-and-clinical-program-updates-at-upcoming-r-d-event 2025-03-19T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrivon-therapeutics-to-showcase-ap3-platform-and-clinical-program-updates-at-upcoming-r-d-event 2025-03-19T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-ht-kit-shows-promising-results-against-gastrointestinal-stromal-tumors-in-preclinical-study 2025-03-19T08:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-ht-kit-shows-promising-results-against-gastrointestinal-stromal-tumors-in-preclinical-study 2025-03-19T08:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-secures-eur500-million-inaugural-rated-public-bond-following-investment-grade-ratings 2025-03-19T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-secures-eur500-million-inaugural-rated-public-bond-following-investment-grade-ratings 2025-03-19T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/lecanemab-s-effectiveness-for-alzheimer-s-may-be-significantly-lower-in-female-patients-study-suggests 2025-03-19T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lecanemab-s-effectiveness-for-alzheimer-s-may-be-significantly-lower-in-female-patients-study-suggests 2025-03-19T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/dassault-systemes-invests-in-click-therapeutics-to-advance-digital-therapeutics-beyond-clinical-trials 2025-03-19T07:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dassault-systemes-invests-in-click-therapeutics-to-advance-digital-therapeutics-beyond-clinical-trials 2025-03-19T07:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/cellares-revolutionizes-cell-therapy-manufacturing-with-automated-platform-for-autoimmune-and-cancer-treatments 2025-03-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellares-revolutionizes-cell-therapy-manufacturing-with-automated-platform-for-autoimmune-and-cancer-treatments 2025-03-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-pioneers-decentralized-clinical-trials-in-oncology-to-overcome-geographic-barriers 2025-03-19T02:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-pioneers-decentralized-clinical-trials-in-oncology-to-overcome-geographic-barriers 2025-03-19T02:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/ir-med-s-pressuresafe-device-shows-90-sensitivity-in-diverse-skin-tone-study-as-company-expands-into-diabetic-foot-ulcer-market 2025-03-19T02:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ir-med-s-pressuresafe-device-shows-90-sensitivity-in-diverse-skin-tone-study-as-company-expands-into-diabetic-foot-ulcer-market 2025-03-19T02:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/tirzepatide-demonstrates-superior-speed-in-achieving-diabetes-control-and-weight-loss-targets 2025-03-19T02:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tirzepatide-demonstrates-superior-speed-in-achieving-diabetes-control-and-weight-loss-targets 2025-03-19T02:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/fruquintinib-sintilimab-combination-meets-primary-endpoint-in-phase-ii-iii-rcc-trial 2025-03-19T01:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fruquintinib-sintilimab-combination-meets-primary-endpoint-in-phase-ii-iii-rcc-trial 2025-03-19T01:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/moon-surgical-secures-fda-clearance-for-ai-powered-scopilot-on-maestro-system 2025-03-19T01:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moon-surgical-secures-fda-clearance-for-ai-powered-scopilot-on-maestro-system 2025-03-19T01:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-groundbreaking-technologies-for-epilepsy-monitoring-embrace-smartwatch-and-minder-implantable-eeg-system 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-groundbreaking-technologies-for-epilepsy-monitoring-embrace-smartwatch-and-minder-implantable-eeg-system 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/madrigal-s-resmetirom-shows-promise-in-nash-treatment-where-others-have-failed 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/madrigal-s-resmetirom-shows-promise-in-nash-treatment-where-others-have-failed 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/galecto-shifts-focus-to-oncology-with-acquisition-of-dual-enl-yeats-flt3-inhibitor-for-aml-treatment 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galecto-shifts-focus-to-oncology-with-acquisition-of-dual-enl-yeats-flt3-inhibitor-for-aml-treatment 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/il-17-and-il-23-inhibitors-show-promising-safety-and-efficacy-profiles-in-elderly-psoriasis-patients 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-17-and-il-23-inhibitors-show-promising-safety-and-efficacy-profiles-in-elderly-psoriasis-patients 2025-03-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aga111-shows-promising-results-in-spinal-fusion-clinical-trial-advances-to-phase-3 2025-03-18T23:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aga111-shows-promising-results-in-spinal-fusion-clinical-trial-advances-to-phase-3 2025-03-18T23:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/valo-health-and-nference-partner-to-accelerate-ai-driven-drug-discovery 2025-03-18T22:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valo-health-and-nference-partner-to-accelerate-ai-driven-drug-discovery 2025-03-18T22:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/nyrada-s-nyr-bi03-shows-promise-in-traumatic-brain-injury-and-begins-phase-1-clinical-trial 2025-03-18T22:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyrada-s-nyr-bi03-shows-promise-in-traumatic-brain-injury-and-begins-phase-1-clinical-trial 2025-03-18T22:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/insulet-expands-omnipod-5-automated-insulin-delivery-system-to-australia-and-three-additional-markets 2025-03-18T20:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insulet-expands-omnipod-5-automated-insulin-delivery-system-to-australia-and-three-additional-markets 2025-03-18T20:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-record-48-first-in-class-innovative-drugs-in-2023 2025-03-18T19:33:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-record-48-first-in-class-innovative-drugs-in-2023 2025-03-18T19:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/cs-diagnostics-partners-with-lachman-consultants-to-fast-track-fda-approval-for-novel-cancer-radiation-therapy-hydrogel 2025-03-18T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cs-diagnostics-partners-with-lachman-consultants-to-fast-track-fda-approval-for-novel-cancer-radiation-therapy-hydrogel 2025-03-18T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-for-johnson-johnson-s-nipocalimab-in-sjogren-s-disease 2025-03-18T19:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-for-johnson-johnson-s-nipocalimab-in-sjogren-s-disease 2025-03-18T19:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-kidney-drug-sevelamer-shows-promise-in-fighting-antibiotic-resistance 2025-03-18T19:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-kidney-drug-sevelamer-shows-promise-in-fighting-antibiotic-resistance 2025-03-18T19:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-hypofractionated-radiation-therapy-safe-and-effective-for-breast-cancer-patients-with-reconstruction 2025-03-18T19:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-shows-hypofractionated-radiation-therapy-safe-and-effective-for-breast-cancer-patients-with-reconstruction 2025-03-18T19:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascelia-pharma-advances-orviglance-nda-following-positive-fda-meeting-submission-planned-for-mid-2025 2025-03-18T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascelia-pharma-advances-orviglance-nda-following-positive-fda-meeting-submission-planned-for-mid-2025 2025-03-18T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/enterobiotix-reports-promising-phase-2a-results-for-novel-microbiome-therapy-in-ibs-c 2025-03-18T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterobiotix-reports-promising-phase-2a-results-for-novel-microbiome-therapy-in-ibs-c 2025-03-18T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/curadel-pharma-advances-first-in-class-zwitterionic-drug-for-ureter-visualization-into-phase-3-trial 2025-03-18T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curadel-pharma-advances-first-in-class-zwitterionic-drug-for-ureter-visualization-into-phase-3-trial 2025-03-18T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-nipocalimab-for-sjogren-s-disease-treatment 2025-03-18T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-nipocalimab-for-sjogren-s-disease-treatment 2025-03-18T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-trainhealth-s-novel-electrical-stimulation-device-for-neurological-rehabilitation 2025-03-18T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-trainhealth-s-novel-electrical-stimulation-device-for-neurological-rehabilitation 2025-03-18T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/cycle-pharmaceuticals-launches-venxxiva-for-cystinuria-treatment-in-the-us 2025-03-18T16:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cycle-pharmaceuticals-launches-venxxiva-for-cystinuria-treatment-in-the-us 2025-03-18T16:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/novotech-forms-strategic-partnership-with-knuh-to-advance-regenerative-medicine-trials-in-south-korea 2025-03-18T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novotech-forms-strategic-partnership-with-knuh-to-advance-regenerative-medicine-trials-in-south-korea 2025-03-18T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/smsbiotech-advances-copd-treatment-with-phase-i-trial-approval-in-australia 2025-03-18T16:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smsbiotech-advances-copd-treatment-with-phase-i-trial-approval-in-australia 2025-03-18T16:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/umecrine-cognition-s-phase-1b-2a-trial-of-golexanolone-for-pbc-faces-temporary-delay-due-to-manufacturing-issues 2025-03-18T16:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umecrine-cognition-s-phase-1b-2a-trial-of-golexanolone-for-pbc-faces-temporary-delay-due-to-manufacturing-issues 2025-03-18T16:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-teva-s-applications-for-uzedy-in-bipolar-disorder-and-ajovy-for-pediatric-migraines 2025-03-18T13:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-teva-s-applications-for-uzedy-in-bipolar-disorder-and-ajovy-for-pediatric-migraines 2025-03-18T13:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/ypsomed-and-camdiab-to-launch-ios-version-of-mylife-loop-automated-insulin-delivery-system 2025-03-18T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ypsomed-and-camdiab-to-launch-ios-version-of-mylife-loop-automated-insulin-delivery-system 2025-03-18T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-liquid-losartan-formulation-for-hypertension-treatment 2025-03-18T13:34:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-liquid-losartan-formulation-for-hypertension-treatment 2025-03-18T13:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/cytrellis-expands-global-reach-ellacor-r-with-micro-coring-r-technology-receives-regulatory-approval-in-canada-and-saudi-arabia 2025-03-18T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytrellis-expands-global-reach-ellacor-r-with-micro-coring-r-technology-receives-regulatory-approval-in-canada-and-saudi-arabia 2025-03-18T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-seeks-uk-approval-for-talicia-its-leading-h-pylori-treatment 2025-03-18T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-seeks-uk-approval-for-talicia-its-leading-h-pylori-treatment 2025-03-18T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-study-reveals-over-20-of-cancer-patients-eligible-for-pan-cancer-therapies 2025-03-18T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-study-reveals-over-20-of-cancer-patients-eligible-for-pan-cancer-therapies 2025-03-18T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/virax-biolabs-launches-clinical-study-to-assess-t-cell-dysfunction-in-post-acute-infection-syndromes 2025-03-18T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virax-biolabs-launches-clinical-study-to-assess-t-cell-dysfunction-in-post-acute-infection-syndromes 2025-03-18T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/madison-scientific-secures-7m-seed-funding-to-advance-smart-hydrocephalus-shunt-technology 2025-03-18T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/madison-scientific-secures-7m-seed-funding-to-advance-smart-hydrocephalus-shunt-technology 2025-03-18T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-s-fabhalta-rapidly-reshapes-pnh-treatment-landscape-as-biosimilars-loom 2025-03-18T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-s-fabhalta-rapidly-reshapes-pnh-treatment-landscape-as-biosimilars-loom 2025-03-18T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-poised-for-growth-with-expanding-rare-disease-portfolio-and-pending-fda-approvals 2025-03-18T10:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-poised-for-growth-with-expanding-rare-disease-portfolio-and-pending-fda-approvals 2025-03-18T10:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-pharma-giants-push-for-us-level-drug-pricing-amid-tariff-tensions 2025-03-18T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-pharma-giants-push-for-us-level-drug-pricing-amid-tariff-tensions 2025-03-18T10:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-mounjaro-demonstrates-superior-efficacy-in-head-to-head-trials-against-diabetes-competitors 2025-03-18T10:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-mounjaro-demonstrates-superior-efficacy-in-head-to-head-trials-against-diabetes-competitors 2025-03-18T10:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-cure-trials-at-croi-2025-show-promise-for-broader-patient-applications 2025-03-18T10:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-cure-trials-at-croi-2025-show-promise-for-broader-patient-applications 2025-03-18T10:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-oncorena-s-ind-for-novel-kidney-specific-cancer-drug-in-dialysis-patients 2025-03-18T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-oncorena-s-ind-for-novel-kidney-specific-cancer-drug-in-dialysis-patients 2025-03-18T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/crossject-reports-positive-6-month-stability-data-for-zepizure-epilepsy-auto-injector 2025-03-18T09:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crossject-reports-positive-6-month-stability-data-for-zepizure-epilepsy-auto-injector 2025-03-18T09:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/cyrano-therapeutics-advances-novel-treatment-for-post-viral-smell-loss-with-soft-mist-technology 2025-03-18T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyrano-therapeutics-advances-novel-treatment-for-post-viral-smell-loss-with-soft-mist-technology 2025-03-18T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/prosense-r-cryoablation-shows-promise-as-non-surgical-alternative-for-early-stage-breast-cancer 2025-03-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prosense-r-cryoablation-shows-promise-as-non-surgical-alternative-for-early-stage-breast-cancer 2025-03-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/start-acquires-carolina-urologic-research-center-to-strengthen-genitourinary-cancer-trial-capabilities 2025-03-18T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/start-acquires-carolina-urologic-research-center-to-strengthen-genitourinary-cancer-trial-capabilities 2025-03-18T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/omega-laboratories-and-cannabix-technologies-validate-breakthrough-marijuana-breath-detection-method 2025-03-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omega-laboratories-and-cannabix-technologies-validate-breakthrough-marijuana-breath-detection-method 2025-03-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-antiviral-obeldesivir-shows-promise-in-treating-ebola-virus-in-primate-study 2025-03-18T07:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-antiviral-obeldesivir-shows-promise-in-treating-ebola-virus-in-primate-study 2025-03-18T07:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/perspective-therapeutics-doses-first-patient-in-combination-therapy-trial-for-advanced-melanoma 2025-03-18T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perspective-therapeutics-doses-first-patient-in-combination-therapy-trial-for-advanced-melanoma 2025-03-18T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-expands-portfolio-to-over-120-assets-reports-financial-results-for-2024 2025-03-18T05:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-expands-portfolio-to-over-120-assets-reports-financial-results-for-2024 2025-03-18T05:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-advances-gene-editing-program-for-alpha-1-antitrypsin-deficiency-with-72-correction-rate 2025-03-18T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-advances-gene-editing-program-for-alpha-1-antitrypsin-deficiency-with-72-correction-rate 2025-03-18T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anixa-biosciences-to-present-novel-ovarian-cancer-car-t-therapy-data-at-asco-2025 2025-03-18T03:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anixa-biosciences-to-present-novel-ovarian-cancer-car-t-therapy-data-at-asco-2025 2025-03-18T03:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-therapeutics-advances-neurology-pipeline-and-fabry-disease-gene-therapy-amid-financial-restructuring 2025-03-18T02:02:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-therapeutics-advances-neurology-pipeline-and-fabry-disease-gene-therapy-amid-financial-restructuring 2025-03-18T02:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/tofersen-shows-promise-in-slowing-progression-of-sod1-motor-neuron-disease 2025-03-18T01:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tofersen-shows-promise-in-slowing-progression-of-sod1-motor-neuron-disease 2025-03-18T01:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-alnylam-s-oxlumo-as-first-treatment-for-ultra-rare-kidney-disease-ph1 2025-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-alnylam-s-oxlumo-as-first-treatment-for-ultra-rare-kidney-disease-ph1 2025-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-gene-therapy-approaches-for-neuromuscular-diseases-promises-and-challenges 2025-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-gene-therapy-approaches-for-neuromuscular-diseases-promises-and-challenges 2025-03-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-nasal-bacteria-successfully-deliver-obesity-drugs-to-brain-bypassing-blood-brain-barrier 2025-03-17T22:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-nasal-bacteria-successfully-deliver-obesity-drugs-to-brain-bypassing-blood-brain-barrier 2025-03-17T22:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/egle-therapeutics-secures-eur9-3-million-in-french-government-funding-to-advance-treg-targeting-cancer-therapies 2025-03-17T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egle-therapeutics-secures-eur9-3-million-in-french-government-funding-to-advance-treg-targeting-cancer-therapies 2025-03-17T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/eteplirsen-shows-dual-benefits-in-duchenne-muscular-dystrophy-slowing-cardiac-decline-and-delaying-loss-of-ambulation 2025-03-17T22:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eteplirsen-shows-dual-benefits-in-duchenne-muscular-dystrophy-slowing-cardiac-decline-and-delaying-loss-of-ambulation 2025-03-17T22:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-povorcitinib-phase-3-trial-results-disappoint-investors-despite-meeting-primary-endpoints 2025-03-17T22:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-s-povorcitinib-phase-3-trial-results-disappoint-investors-despite-meeting-primary-endpoints 2025-03-17T22:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/new-ai-powered-line-clearance-solution-promises-85-time-savings-for-pharmaceutical-manufacturing 2025-03-17T20:02:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ai-powered-line-clearance-solution-promises-85-time-savings-for-pharmaceutical-manufacturing 2025-03-17T20:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/atezolizumab-plus-chemotherapy-shows-promising-results-for-advanced-thymic-carcinoma 2025-03-17T19:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atezolizumab-plus-chemotherapy-shows-promising-results-for-advanced-thymic-carcinoma 2025-03-17T19:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/savara-to-present-phase-3-impala-2-trial-data-on-molgramostim-for-rare-lung-disease-at-multiple-international-conferences 2025-03-17T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-to-present-phase-3-impala-2-trial-data-on-molgramostim-for-rare-lung-disease-at-multiple-international-conferences 2025-03-17T19:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/vertanical-achieves-phase-3-success-with-novel-non-opioid-pain-medication 2025-03-17T19:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertanical-achieves-phase-3-success-with-novel-non-opioid-pain-medication 2025-03-17T19:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-partners-with-alteogen-to-develop-subcutaneous-oncology-treatments-using-novel-hyaluronidase-technology 2025-03-17T19:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-partners-with-alteogen-to-develop-subcutaneous-oncology-treatments-using-novel-hyaluronidase-technology 2025-03-17T19:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-bioarctic-s-exidavnemab-for-multiple-system-atrophy 2025-03-17T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-bioarctic-s-exidavnemab-for-multiple-system-atrophy 2025-03-17T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/curevo-secures-110-million-series-b-funding-to-advance-next-generation-shingles-vaccine 2025-03-17T17:03:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevo-secures-110-million-series-b-funding-to-advance-next-generation-shingles-vaccine 2025-03-17T17:03:28+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-s-dyne-251-shows-unprecedented-functional-improvements-in-duchenne-muscular-dystrophy-trial 2025-03-17T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-s-dyne-251-shows-unprecedented-functional-improvements-in-duchenne-muscular-dystrophy-trial 2025-03-17T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/filament-health-s-botanical-psilocybin-shows-promise-in-reducing-alcohol-consumption-in-phase-2-trial 2025-03-17T16:39:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/filament-health-s-botanical-psilocybin-shows-promise-in-reducing-alcohol-consumption-in-phase-2-trial 2025-03-17T16:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-rona-therapeutics-ind-for-phase-2-study-of-rn0361-in-hypertriglyceridemia 2025-03-17T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-rona-therapeutics-ind-for-phase-2-study-of-rn0361-in-hypertriglyceridemia 2025-03-17T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-to-seek-orphan-drug-designation-for-novel-rett-syndrome-treatment 2025-03-17T16:38:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marvel-biosciences-to-seek-orphan-drug-designation-for-novel-rett-syndrome-treatment 2025-03-17T16:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-cellphire-s-clph-511-for-acute-hemorrhage-treatment 2025-03-17T16:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-cellphire-s-clph-511-for-acute-hemorrhage-treatment 2025-03-17T16:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-ipo-market-faces-extended-slump-through-2026-amid-regulatory-uncertainty-and-poor-returns 2025-03-17T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-ipo-market-faces-extended-slump-through-2026-amid-regulatory-uncertainty-and-poor-returns 2025-03-17T16:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-strengthens-precision-medicine-platform-with-strategic-deep-6-ai-acquisition 2025-03-17T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-strengthens-precision-medicine-platform-with-strategic-deep-6-ai-acquisition 2025-03-17T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/fortress-biotech-and-partex-form-strategic-ai-partnership-to-accelerate-drug-discovery-and-development 2025-03-17T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fortress-biotech-and-partex-form-strategic-ai-partnership-to-accelerate-drug-discovery-and-development 2025-03-17T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-acquires-european-cell-therapy-biotech-in-deal-worth-up-to-1-billion 2025-03-17T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-acquires-european-cell-therapy-biotech-in-deal-worth-up-to-1-billion 2025-03-17T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/perimeter-medical-submits-fda-premarket-approval-for-ai-enabled-oct-system-in-breast-cancer-surgery 2025-03-17T16:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perimeter-medical-submits-fda-premarket-approval-for-ai-enabled-oct-system-in-breast-cancer-surgery 2025-03-17T16:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/opthea-s-clinical-trial-failure-threatens-company-survival-and-impacts-regal-partners 2025-03-17T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opthea-s-clinical-trial-failure-threatens-company-survival-and-impacts-regal-partners 2025-03-17T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/springbok-analytics-pioneers-ai-driven-mri-analysis-in-landmark-pediatric-fshd-study 2025-03-17T16:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/springbok-analytics-pioneers-ai-driven-mri-analysis-in-landmark-pediatric-fshd-study 2025-03-17T16:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-first-human-trial-of-lassarab-vaccine-for-deadly-lassa-fever 2025-03-17T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-launches-first-human-trial-of-lassarab-vaccine-for-deadly-lassa-fever 2025-03-17T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/qxo-secures-830-million-in-private-placement-and-prices-500-million-common-stock-offering-for-beacon-acquisition 2025-03-17T16:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qxo-secures-830-million-in-private-placement-and-prices-500-million-common-stock-offering-for-beacon-acquisition 2025-03-17T16:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-to-present-new-aficamten-data-at-acc-2025-insights-on-metabolism-combination-therapy-and-long-term-cardiac-effects 2025-03-17T14:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-to-present-new-aficamten-data-at-acc-2025-insights-on-metabolism-combination-therapy-and-long-term-cardiac-effects 2025-03-17T14:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-acquires-esobiotec-for-up-to-1-billion-to-transform-cancer-cell-therapy 2025-03-17T14:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-acquires-esobiotec-for-up-to-1-billion-to-transform-cancer-cell-therapy 2025-03-17T14:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/prokidney-reports-positive-progress-in-rilparencel-development-for-advanced-ckd 2025-03-17T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prokidney-reports-positive-progress-in-rilparencel-development-for-advanced-ckd 2025-03-17T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/asimov-expands-strategic-partnerships-to-accelerate-biologics-development-through-cho-edge-platform 2025-03-17T13:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asimov-expands-strategic-partnerships-to-accelerate-biologics-development-through-cho-edge-platform 2025-03-17T13:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/chance-pharma-secures-new-funding-to-advance-phase-iii-trials-of-innovative-inhalation-therapy 2025-03-17T13:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chance-pharma-secures-new-funding-to-advance-phase-iii-trials-of-innovative-inhalation-therapy 2025-03-17T13:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/oncimmune-enters-administration-after-failed-sale-attempts-and-funding-shortfall 2025-03-17T13:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncimmune-enters-administration-after-failed-sale-attempts-and-funding-shortfall 2025-03-17T13:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/cidara-s-cd388-shows-promise-as-universal-influenza-preventative-in-nature-microbiology-publication 2025-03-17T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cidara-s-cd388-shows-promise-as-universal-influenza-preventative-in-nature-microbiology-publication 2025-03-17T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/mindmed-appoints-matt-wiley-as-chief-commercial-officer-to-lead-mm120-launch-strategy 2025-03-17T13:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindmed-appoints-matt-wiley-as-chief-commercial-officer-to-lead-mm120-launch-strategy 2025-03-17T13:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-xeris-biopharma-s-gvoke-vialdx-as-first-ready-to-dilute-liquid-glucagon-for-gastrointestinal-diagnostics 2025-03-17T13:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-xeris-biopharma-s-gvoke-vialdx-as-first-ready-to-dilute-liquid-glucagon-for-gastrointestinal-diagnostics 2025-03-17T13:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/avenacy-expands-injectable-antibiotic-portfolio-with-launch-of-five-critical-products-in-u-s-market 2025-03-17T13:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avenacy-expands-injectable-antibiotic-portfolio-with-launch-of-five-critical-products-in-u-s-market 2025-03-17T13:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-pharmaceutical-to-acquire-swiss-adc-pioneer-araris-biotech-for-up-to-1-14-billion 2025-03-17T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-pharmaceutical-to-acquire-swiss-adc-pioneer-araris-biotech-for-up-to-1-14-billion 2025-03-17T13:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/anocca-secures-regulatory-approval-for-first-in-human-pancreatic-cancer-trial-using-novel-tcr-t-cell-therapy 2025-03-17T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anocca-secures-regulatory-approval-for-first-in-human-pancreatic-cancer-trial-using-novel-tcr-t-cell-therapy 2025-03-17T13:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/solascure-initiates-new-phase-ii-trial-for-aurase-wound-gel-in-chronic-wound-treatment 2025-03-17T13:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solascure-initiates-new-phase-ii-trial-for-aurase-wound-gel-in-chronic-wound-treatment 2025-03-17T13:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-povorcitinib-shows-significant-efficacy-in-phase-3-trials-for-hidradenitis-suppurativa 2025-03-17T13:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-s-povorcitinib-shows-significant-efficacy-in-phase-3-trials-for-hidradenitis-suppurativa 2025-03-17T13:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/archer-platform-launches-at-cambridge-university-hospitals-to-revolutionize-clinical-trial-data-management 2025-03-17T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archer-platform-launches-at-cambridge-university-hospitals-to-revolutionize-clinical-trial-data-management 2025-03-17T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-and-entera-bio-collaborate-to-develop-first-oral-glp-1-glucagon-dual-agonist-for-obesity-treatment 2025-03-17T13:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-and-entera-bio-collaborate-to-develop-first-oral-glp-1-glucagon-dual-agonist-for-obesity-treatment 2025-03-17T13:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-vtv-therapeutics-cadisegliatin-for-type-1-diabetes 2025-03-17T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-vtv-therapeutics-cadisegliatin-for-type-1-diabetes 2025-03-17T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-linvoseltamab-shows-promising-results-in-phase-1b-trial-for-multiple-myeloma 2025-03-17T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-linvoseltamab-shows-promising-results-in-phase-1b-trial-for-multiple-myeloma 2025-03-17T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-advances-psychedelic-therapy-pipeline-with-key-clinical-milestones-and-extended-financial-runway 2025-03-17T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-advances-psychedelic-therapy-pipeline-with-key-clinical-milestones-and-extended-financial-runway 2025-03-17T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-eneboparatide-meets-primary-endpoint-in-phase-iii-trial-for-hypoparathyroidism 2025-03-17T10:33:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-eneboparatide-meets-primary-endpoint-in-phase-iii-trial-for-hypoparathyroidism 2025-03-17T10:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/maxion-therapeutics-secures-72m-series-a-to-advance-novel-knotbody-platform-for-ion-channel-diseases 2025-03-17T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxion-therapeutics-secures-72m-series-a-to-advance-novel-knotbody-platform-for-ion-channel-diseases 2025-03-17T10:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/peptris-technologies-licenses-india-s-first-ai-discovered-drug-candidate-for-duchenne-muscular-dystrophy 2025-03-17T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptris-technologies-licenses-india-s-first-ai-discovered-drug-candidate-for-duchenne-muscular-dystrophy 2025-03-17T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/latigo-secures-150m-series-b-to-advance-non-opioid-pain-medications-through-late-stage-trials 2025-03-17T10:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latigo-secures-150m-series-b-to-advance-non-opioid-pain-medications-through-late-stage-trials 2025-03-17T10:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-bms-s-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2025-03-17T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-bms-s-breyanzi-for-relapsed-or-refractory-follicular-lymphoma 2025-03-17T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/pacylex-initiates-phase-1-2-trial-of-first-in-class-n-myristoyltransferase-inhibitor-zelenirstat-in-relapsed-refractory-aml 2025-03-17T09:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacylex-initiates-phase-1-2-trial-of-first-in-class-n-myristoyltransferase-inhibitor-zelenirstat-in-relapsed-refractory-aml 2025-03-17T09:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-enters-obesity-market-with-major-deal-as-j-j-abandons-next-gen-darzalex-development 2025-03-17T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-enters-obesity-market-with-major-deal-as-j-j-abandons-next-gen-darzalex-development 2025-03-17T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-bio101-shows-promising-phase-ii-results-in-sarcopenia-treatment-advancing-to-phase-iii 2025-03-17T07:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biophytis-bio101-shows-promising-phase-ii-results-in-sarcopenia-treatment-advancing-to-phase-iii 2025-03-17T07:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-chinese-cancer-therapy-uses-modified-viruses-to-transform-tumors-into-foreign-tissue 2025-03-17T07:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-chinese-cancer-therapy-uses-modified-viruses-to-transform-tumors-into-foreign-tissue 2025-03-17T07:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/ms-20-shows-remarkable-efficacy-as-add-on-therapy-for-ulcerative-colitis-in-clinical-trial 2025-03-17T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ms-20-shows-remarkable-efficacy-as-add-on-therapy-for-ulcerative-colitis-in-clinical-trial 2025-03-17T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/avance-clinical-expands-asia-pacific-footprint-with-four-strategic-partnerships-in-taiwan 2025-03-17T02:32:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avance-clinical-expands-asia-pacific-footprint-with-four-strategic-partnerships-in-taiwan 2025-03-17T02:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/retinalogik-secures-1-1m-funding-and-health-canada-approval-for-vr-ai-eye-care-platform 2025-03-17T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retinalogik-secures-1-1m-funding-and-health-canada-approval-for-vr-ai-eye-care-platform 2025-03-17T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cepi-awards-5-million-to-nagasaki-university-for-revolutionary-nanoball-mrna-vaccine-platform 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepi-awards-5-million-to-nagasaki-university-for-revolutionary-nanoball-mrna-vaccine-platform 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-rems-requirement-for-tryvio-simplifying-access-to-novel-hypertension-treatment 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-rems-requirement-for-tryvio-simplifying-access-to-novel-hypertension-treatment 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/esr1-mutations-in-breast-cancer-emerging-biomarker-reshapes-treatment-strategies 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esr1-mutations-in-breast-cancer-emerging-biomarker-reshapes-treatment-strategies 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/benralizumab-shows-superior-long-term-outcomes-in-eosinophilic-granulomatosis-with-polyangiitis 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benralizumab-shows-superior-long-term-outcomes-in-eosinophilic-granulomatosis-with-polyangiitis 2025-03-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-s-gene-therapy-for-limb-girdle-muscular-dystrophy-shows-sustained-5-year-safety-profile 2025-03-16T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-s-gene-therapy-for-limb-girdle-muscular-dystrophy-shows-sustained-5-year-safety-profile 2025-03-16T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/puxitatug-samrotecan-shows-promise-in-advanced-endometrial-cancer-with-38-response-rate 2025-03-16T22:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puxitatug-samrotecan-shows-promise-in-advanced-endometrial-cancer-with-38-response-rate 2025-03-16T22:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/luveltamab-tazevibulin-shows-promising-results-in-platinum-resistant-ovarian-cancer-with-low-to-high-fra-expression 2025-03-16T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luveltamab-tazevibulin-shows-promising-results-in-platinum-resistant-ovarian-cancer-with-low-to-high-fra-expression 2025-03-16T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/allchem-lifescience-files-for-ipo-to-raise-190-crore-expands-api-manufacturing-capabilities 2025-03-16T19:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allchem-lifescience-files-for-ipo-to-raise-190-crore-expands-api-manufacturing-capabilities 2025-03-16T19:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-drug-efavirenz-shows-promise-as-potential-chikungunya-treatment-in-iit-roorkee-study 2025-03-16T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-drug-efavirenz-shows-promise-as-potential-chikungunya-treatment-in-iit-roorkee-study 2025-03-16T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-ps10-million-clinical-trial-on-puberty-blockers-following-cass-review-recommendations 2025-03-16T19:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-launches-ps10-million-clinical-trial-on-puberty-blockers-following-cass-review-recommendations 2025-03-16T19:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-launches-first-covid-19-human-challenge-trial-with-five-volunteers 2025-03-16T19:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-launches-first-covid-19-human-challenge-trial-with-five-volunteers 2025-03-16T19:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/digital-innovation-a-lifeline-for-rare-disease-drug-development-and-patient-care 2025-03-16T17:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-innovation-a-lifeline-for-rare-disease-drug-development-and-patient-care 2025-03-16T17:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-immunoglobulin-therapy-shows-promising-results-in-post-polio-syndrome-clinical-trial 2025-03-16T16:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-immunoglobulin-therapy-shows-promising-results-in-post-polio-syndrome-clinical-trial 2025-03-16T16:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-secures-110m-series-e-funding-achieves-unicorn-status-for-ai-driven-drug-discovery 2025-03-16T01:33:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-secures-110m-series-e-funding-achieves-unicorn-status-for-ai-driven-drug-discovery 2025-03-16T01:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-faces-multiple-downgrades-after-discontinuing-lead-program-luvelta 2025-03-16T01:33:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-faces-multiple-downgrades-after-discontinuing-lead-program-luvelta 2025-03-16T01:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-reports-promising-results-for-luvelta-in-platinum-resistant-ovarian-cancer-trial 2025-03-16T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-reports-promising-results-for-luvelta-in-platinum-resistant-ovarian-cancer-trial 2025-03-16T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/zimberelimab-plus-lenvatinib-shows-promise-in-advanced-cervical-cancer-after-ici-failure 2025-03-15T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zimberelimab-plus-lenvatinib-shows-promise-in-advanced-cervical-cancer-after-ici-failure 2025-03-15T22:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/afuresertib-plus-paclitaxel-fails-to-improve-survival-in-platinum-resistant-ovarian-cancer-trial 2025-03-15T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/afuresertib-plus-paclitaxel-fails-to-improve-survival-in-platinum-resistant-ovarian-cancer-trial 2025-03-15T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-recommends-protocol-revisions-for-zydus-healthcare-s-empagliflozin-metoprolol-combination-therapy 2025-03-15T19:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-recommends-protocol-revisions-for-zydus-healthcare-s-empagliflozin-metoprolol-combination-therapy 2025-03-15T19:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/cadonilimab-plus-lenvatinib-shows-promise-in-advanced-endometrial-cancer-after-platinum-failure 2025-03-15T19:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadonilimab-plus-lenvatinib-shows-promise-in-advanced-endometrial-cancer-after-platinum-failure 2025-03-15T19:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/olaparib-durvalumab-combination-shows-broad-pfs-benefits-across-pmmr-endometrial-cancer-subgroups 2025-03-15T19:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olaparib-durvalumab-combination-shows-broad-pfs-benefits-across-pmmr-endometrial-cancer-subgroups 2025-03-15T19:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/benuvia-operations-secures-anvisa-gmp-certification-expanding-pharmaceutical-manufacturing-capabilities-in-brazil 2025-03-15T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benuvia-operations-secures-anvisa-gmp-certification-expanding-pharmaceutical-manufacturing-capabilities-in-brazil 2025-03-15T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-shows-promising-results-in-dmmr-msi-h-endometrial-cancer-potentially-eliminating-need-for-surgery 2025-03-15T16:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-shows-promising-results-in-dmmr-msi-h-endometrial-cancer-potentially-eliminating-need-for-surgery 2025-03-15T16:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/elahere-shows-32-reduction-in-death-risk-for-platinum-resistant-ovarian-cancer-in-final-mirasol-trial-analysis 2025-03-15T13:36:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elahere-shows-32-reduction-in-death-risk-for-platinum-resistant-ovarian-cancer-in-final-mirasol-trial-analysis 2025-03-15T13:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/ioncologi-acquires-targimmune-therapeutics-to-advance-novel-immunotherapies-for-solid-tumors 2025-03-15T13:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ioncologi-acquires-targimmune-therapeutics-to-advance-novel-immunotherapies-for-solid-tumors 2025-03-15T13:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-teknova-and-pluristyx-partner-to-advance-allogeneic-cell-therapy-manufacturing-with-novel-cryopreservation-system 2025-03-15T13:36:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-teknova-and-pluristyx-partner-to-advance-allogeneic-cell-therapy-manufacturing-with-novel-cryopreservation-system 2025-03-15T13:36:54+00:00 hourly 0.9 https://trial.medpath.com/news/willow-biosciences-sells-operating-subsidiary-for-us-3-38-million-in-strategic-divestiture 2025-03-15T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/willow-biosciences-sells-operating-subsidiary-for-us-3-38-million-in-strategic-divestiture 2025-03-15T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/optimizing-treatment-strategies-for-relapsed-multiple-myeloma-from-car-t-cell-therapy-to-novel-combinations 2025-03-15T05:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optimizing-treatment-strategies-for-relapsed-multiple-myeloma-from-car-t-cell-therapy-to-novel-combinations 2025-03-15T05:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/five-years-later-covid-19-s-lasting-impact-on-oncology-care-and-research 2025-03-15T02:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-years-later-covid-19-s-lasting-impact-on-oncology-care-and-research 2025-03-15T02:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-maintains-high-pharmaceutical-rebate-rates-despite-industry-pushback 2025-03-15T02:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-maintains-high-pharmaceutical-rebate-rates-despite-industry-pushback 2025-03-15T02:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/ilet-bionic-pancreas-shows-equal-efficacy-in-primary-care-and-specialty-settings-for-type-1-diabetes 2025-03-15T01:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ilet-bionic-pancreas-shows-equal-efficacy-in-primary-care-and-specialty-settings-for-type-1-diabetes 2025-03-15T01:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-5000-crore-pharma-r-d-fund-to-boost-innovation-and-reduce-import-dependence 2025-03-15T01:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-5000-crore-pharma-r-d-fund-to-boost-innovation-and-reduce-import-dependence 2025-03-15T01:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/latigo-secures-150m-funding-to-advance-non-opioid-pain-treatment-in-competition-with-vertex 2025-03-15T01:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latigo-secures-150m-funding-to-advance-non-opioid-pain-treatment-in-competition-with-vertex 2025-03-15T01:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-felzartamab-shows-promising-results-in-iga-nephropathy-phase-2-trial 2025-03-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-s-felzartamab-shows-promising-results-in-iga-nephropathy-phase-2-trial 2025-03-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hu6-shows-promise-in-treating-obesity-related-heart-failure-by-reducing-body-fat-while-preserving-muscle-mass 2025-03-14T23:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hu6-shows-promise-in-treating-obesity-related-heart-failure-by-reducing-body-fat-while-preserving-muscle-mass 2025-03-14T23:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/syngene-international-expands-global-footprint-with-50-million-us-biologics-facility-acquisition 2025-03-14T22:04:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syngene-international-expands-global-footprint-with-50-million-us-biologics-facility-acquisition 2025-03-14T22:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/moscow-s-pharmaceutical-sector-expands-with-37-new-medicines-and-monoclonal-antibody-production 2025-03-14T22:04:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moscow-s-pharmaceutical-sector-expands-with-37-new-medicines-and-monoclonal-antibody-production 2025-03-14T22:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/exopten-shows-promising-results-for-spinal-cord-injury-recovery-in-preclinical-study 2025-03-14T22:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exopten-shows-promising-results-for-spinal-cord-injury-recovery-in-preclinical-study 2025-03-14T22:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-tests-herpes-virus-based-gene-therapy-for-neurogenic-bladder-in-spinal-cord-injury-patients 2025-03-14T22:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-trial-tests-herpes-virus-based-gene-therapy-for-neurogenic-bladder-in-spinal-cord-injury-patients 2025-03-14T22:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-invests-10-million-in-c2n-diagnostics-to-advance-brain-health-diagnostics 2025-03-14T19:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-invests-10-million-in-c2n-diagnostics-to-advance-brain-health-diagnostics 2025-03-14T19:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-accelerates-flu-vaccine-production-for-2025-26-season-amid-severe-current-outbreak 2025-03-14T19:34:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-accelerates-flu-vaccine-production-for-2025-26-season-amid-severe-current-outbreak 2025-03-14T19:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-expands-pemvidutide-testing-to-alcohol-use-disorder-and-liver-disease 2025-03-14T19:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-expands-pemvidutide-testing-to-alcohol-use-disorder-and-liver-disease 2025-03-14T19:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/accropeutics-secures-12-million-series-b-financing-to-advance-novel-therapeutics-for-immune-mediated-diseases 2025-03-14T19:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accropeutics-secures-12-million-series-b-financing-to-advance-novel-therapeutics-for-immune-mediated-diseases 2025-03-14T19:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/circulating-dna-rna-market-set-to-triple-to-16-4-billion-by-2032-driven-by-patent-innovations 2025-03-14T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circulating-dna-rna-market-set-to-triple-to-16-4-billion-by-2032-driven-by-patent-innovations 2025-03-14T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ostiserene-new-single-dose-treatment-for-canine-otitis-externa 2025-03-14T19:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ostiserene-new-single-dose-treatment-for-canine-otitis-externa 2025-03-14T19:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-sacituzumab-govitecan-s-superior-efficacy-in-hr-her2-metastatic-breast-cancer 2025-03-14T19:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-sacituzumab-govitecan-s-superior-efficacy-in-hr-her2-metastatic-breast-cancer 2025-03-14T19:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/weight-loss-drugs-wegovy-and-zepbound-not-cost-effective-at-current-prices-study-finds 2025-03-14T19:05:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-loss-drugs-wegovy-and-zepbound-not-cost-effective-at-current-prices-study-finds 2025-03-14T19:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-partners-with-charles-river-to-advance-fibroblast-based-therapy-for-diabetic-foot-ulcers 2025-03-14T19:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrobiologics-partners-with-charles-river-to-advance-fibroblast-based-therapy-for-diabetic-foot-ulcers 2025-03-14T19:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-launches-nih-funded-clinical-trials-to-address-long-covid-symptoms 2025-03-14T19:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainehealth-launches-nih-funded-clinical-trials-to-address-long-covid-symptoms 2025-03-14T19:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/surf-bio-strengthens-leadership-team-with-cmc-expert-doug-hecker-to-advance-subcutaneous-biologic-delivery-platform 2025-03-14T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surf-bio-strengthens-leadership-team-with-cmc-expert-doug-hecker-to-advance-subcutaneous-biologic-delivery-platform 2025-03-14T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/biolexis-therapeutics-confirms-novel-allosteric-mechanism-for-oral-glp-1-receptor-agonist 2025-03-14T16:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biolexis-therapeutics-confirms-novel-allosteric-mechanism-for-oral-glp-1-receptor-agonist 2025-03-14T16:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-j-j-s-ai-enhanced-monarch-robot-for-improved-lung-cancer-diagnosis 2025-03-14T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-j-j-s-ai-enhanced-monarch-robot-for-improved-lung-cancer-diagnosis 2025-03-14T16:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-first-vaccine-against-epizootic-haemorrhagic-disease-for-cattle-in-eu 2025-03-14T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-first-vaccine-against-epizootic-haemorrhagic-disease-for-cattle-in-eu 2025-03-14T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-promise-in-reducing-ige-levels-in-food-allergy-patients 2025-03-14T16:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-promise-in-reducing-ige-levels-in-food-allergy-patients 2025-03-14T16:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/neuraceq-r-pet-imaging-agent-to-launch-in-hong-kong-advancing-alzheimer-s-diagnosis-capabilities 2025-03-14T16:32:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuraceq-r-pet-imaging-agent-to-launch-in-hong-kong-advancing-alzheimer-s-diagnosis-capabilities 2025-03-14T16:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/hkust-and-siic-launch-hk-600-million-biotechnology-fund-to-accelerate-healthcare-innovation 2025-03-14T16:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hkust-and-siic-launch-hk-600-million-biotechnology-fund-to-accelerate-healthcare-innovation 2025-03-14T16:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/panthera-biopartners-secures-ps20m-in-clinical-trial-contracts-amid-uk-smo-sector-growth 2025-03-14T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panthera-biopartners-secures-ps20m-in-clinical-trial-contracts-amid-uk-smo-sector-growth 2025-03-14T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/autonomix-medical-completes-integration-of-apex-6-generator-advancing-toward-2025-clinical-trials-for-pancreatic-cancer-pain 2025-03-14T16:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autonomix-medical-completes-integration-of-apex-6-generator-advancing-toward-2025-clinical-trials-for-pancreatic-cancer-pain 2025-03-14T16:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/splicebio-initiates-first-in-human-trial-of-dual-aav-gene-therapy-for-stargardt-disease 2025-03-14T13:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splicebio-initiates-first-in-human-trial-of-dual-aav-gene-therapy-for-stargardt-disease 2025-03-14T13:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-iluvien-label-expansion-for-chronic-non-infectious-uveitis-treatment 2025-03-14T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-iluvien-label-expansion-for-chronic-non-infectious-uveitis-treatment 2025-03-14T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-et-600-meets-bioequivalence-endpoints-for-central-diabetes-insipidus-treatment 2025-03-14T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-et-600-meets-bioequivalence-endpoints-for-central-diabetes-insipidus-treatment 2025-03-14T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-sycume-r-first-igf-1r-antibody-for-thyroid-eye-disease-in-70-years 2025-03-14T10:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-sycume-r-first-igf-1r-antibody-for-thyroid-eye-disease-in-70-years 2025-03-14T10:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-commits-ps121-million-to-revitalize-clinical-trial-sector-following-o-shaughnessy-review 2025-03-14T08:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-commits-ps121-million-to-revitalize-clinical-trial-sector-following-o-shaughnessy-review 2025-03-14T08:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/antibody-drug-conjugates-revolutionize-treatment-landscape-for-metastatic-breast-cancer 2025-03-14T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antibody-drug-conjugates-revolutionize-treatment-landscape-for-metastatic-breast-cancer 2025-03-14T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-wins-two-major-awards-for-ai-driven-cancer-diagnostics-and-immunology-solutions 2025-03-14T03:02:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bostongene-wins-two-major-awards-for-ai-driven-cancer-diagnostics-and-immunology-solutions 2025-03-14T03:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-s-dna-encoded-monoclonal-antibodies-show-durable-72-week-expression-without-immune-rejection-in-covid-19-trial 2025-03-14T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-s-dna-encoded-monoclonal-antibodies-show-durable-72-week-expression-without-immune-rejection-in-covid-19-trial 2025-03-14T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-and-crispr-therapeutics-form-300-million-joint-venture-to-advance-gene-editing-therapies 2025-03-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-and-crispr-therapeutics-form-300-million-joint-venture-to-advance-gene-editing-therapies 2025-03-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/telix-pharmaceuticals-expands-radiopharmaceutical-portfolio-with-strategic-fap-targeting-acquisition 2025-03-13T19:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telix-pharmaceuticals-expands-radiopharmaceutical-portfolio-with-strategic-fap-targeting-acquisition 2025-03-13T19:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/vivani-medical-achieves-first-glp-1-implant-and-full-enrollment-in-liberate-1-trial-for-obesity-treatment 2025-03-13T19:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivani-medical-achieves-first-glp-1-implant-and-full-enrollment-in-liberate-1-trial-for-obesity-treatment 2025-03-13T19:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-secures-20-million-in-amended-royalty-deal-with-healthcare-royalty-for-renal-cancer-diagnostic 2025-03-13T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-secures-20-million-in-amended-royalty-deal-with-healthcare-royalty-for-renal-cancer-diagnostic 2025-03-13T17:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-secures-eur185-million-royalty-financing-deal-with-hcrx-restructures-convertible-debt 2025-03-13T16:38:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-secures-eur185-million-royalty-financing-deal-with-hcrx-restructures-convertible-debt 2025-03-13T16:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/faeth-therapeutics-advances-novel-three-pronged-approach-for-metabolism-driven-cancers-with-promising-preclinical-results 2025-03-13T16:37:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faeth-therapeutics-advances-novel-three-pronged-approach-for-metabolism-driven-cancers-with-promising-preclinical-results 2025-03-13T16:37:08+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-reaches-50-enrollment-milestone-in-phase-3-trial-for-novel-dry-amd-treatment 2025-03-13T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stealth-biotherapeutics-reaches-50-enrollment-milestone-in-phase-3-trial-for-novel-dry-amd-treatment 2025-03-13T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-uplizna-shows-sustained-efficacy-in-myasthenia-gravis-patients-through-one-year 2025-03-13T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-uplizna-shows-sustained-efficacy-in-myasthenia-gravis-patients-through-one-year 2025-03-13T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/helix-research-network-reveals-genomic-screening-improves-patient-care-and-risk-identification-at-acmg-2025 2025-03-13T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helix-research-network-reveals-genomic-screening-improves-patient-care-and-risk-identification-at-acmg-2025 2025-03-13T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-and-fresenius-kabi-reach-settlement-in-denosumab-biosimilar-litigation 2025-03-13T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-and-fresenius-kabi-reach-settlement-in-denosumab-biosimilar-litigation 2025-03-13T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-antibodies-secures-10m-partnership-for-ai-driven-cancer-therapeutics-development 2025-03-13T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoprecise-antibodies-secures-10m-partnership-for-ai-driven-cancer-therapeutics-development 2025-03-13T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/immorta-bio-s-senovax-shows-tumor-regression-across-multiple-cancer-types-in-preclinical-studies 2025-03-13T16:35:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immorta-bio-s-senovax-shows-tumor-regression-across-multiple-cancer-types-in-preclinical-studies 2025-03-13T16:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-dyne-101-shows-promise-for-accelerated-approval-pathway-in-dm1 2025-03-13T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-dyne-101-shows-promise-for-accelerated-approval-pathway-in-dm1 2025-03-13T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-spineart-s-perla-r-app-for-use-with-ecential-robotics-op-ntm-navigation-platform 2025-03-13T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-spineart-s-perla-r-app-for-use-with-ecential-robotics-op-ntm-navigation-platform 2025-03-13T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-for-rewalk-7-exoskeleton-for-spinal-cord-injury-patients 2025-03-13T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-for-rewalk-7-exoskeleton-for-spinal-cord-injury-patients 2025-03-13T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/senate-confirms-makary-and-bhattacharya-to-lead-fda-and-nih-amid-healthcare-reform-push 2025-03-13T16:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-confirms-makary-and-bhattacharya-to-lead-fda-and-nih-amid-healthcare-reform-push 2025-03-13T16:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/cosciens-biopharma-advances-oat-derived-anti-inflammatory-compound-to-phase-2a-following-successful-safety-trial 2025-03-13T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosciens-biopharma-advances-oat-derived-anti-inflammatory-compound-to-phase-2a-following-successful-safety-trial 2025-03-13T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/exicure-secures-australian-patent-for-novel-cancer-treatment-targeting-cxcr4-and-gpcrx 2025-03-13T15:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exicure-secures-australian-patent-for-novel-cancer-treatment-targeting-cxcr4-and-gpcrx 2025-03-13T15:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/mainz-biomed-and-liquid-biosciences-develop-breakthrough-blood-test-for-pancreatic-cancer-detection 2025-03-13T14:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainz-biomed-and-liquid-biosciences-develop-breakthrough-blood-test-for-pancreatic-cancer-detection 2025-03-13T14:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/major-insulin-manufacturers-agree-to-35-monthly-price-caps-in-state-settlements 2025-03-13T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-insulin-manufacturers-agree-to-35-monthly-price-caps-in-state-settlements 2025-03-13T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/mallinckrodt-and-endo-to-merge-in-6-7b-deal-creating-pharmaceutical-powerhouse 2025-03-13T14:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mallinckrodt-and-endo-to-merge-in-6-7b-deal-creating-pharmaceutical-powerhouse 2025-03-13T14:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-and-hologen-ai-form-430-million-strategic-collaboration-to-advance-parkinson-s-disease-gene-therapy 2025-03-13T14:02:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-and-hologen-ai-form-430-million-strategic-collaboration-to-advance-parkinson-s-disease-gene-therapy 2025-03-13T14:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/fuse-oncology-and-acro-forge-strategic-partnership-to-standardize-radiation-oncology-clinical-pathways 2025-03-13T13:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fuse-oncology-and-acro-forge-strategic-partnership-to-standardize-radiation-oncology-clinical-pathways 2025-03-13T13:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-pds-biotech-s-novel-immunotherapy-combination-for-metastatic-colorectal-cancer-trial 2025-03-13T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-pds-biotech-s-novel-immunotherapy-combination-for-metastatic-colorectal-cancer-trial 2025-03-13T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-phase-2-trial-of-tpst-1495-for-familial-adenomatous-polyposis-treatment 2025-03-13T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-phase-2-trial-of-tpst-1495-for-familial-adenomatous-polyposis-treatment 2025-03-13T13:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/new-york-man-becomes-first-in-state-to-be-cured-of-sickle-cell-disease-with-lyfgenia-gene-therapy 2025-03-13T13:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-york-man-becomes-first-in-state-to-be-cured-of-sickle-cell-disease-with-lyfgenia-gene-therapy 2025-03-13T13:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/hypersomnia-pipeline-shows-promise-with-10-emerging-therapies-in-development 2025-03-13T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypersomnia-pipeline-shows-promise-with-10-emerging-therapies-in-development 2025-03-13T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-rxulti-for-adolescent-schizophrenia-treatment 2025-03-13T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-rxulti-for-adolescent-schizophrenia-treatment 2025-03-13T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/uflex-secures-fda-approval-for-recycled-polyethylene-in-food-packaging-a-first-for-indian-companies 2025-03-13T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uflex-secures-fda-approval-for-recycled-polyethylene-in-food-packaging-a-first-for-indian-companies 2025-03-13T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-early-feasibility-study-for-valcare-medical-s-amend-trans-septal-system-for-mitral-regurgitation 2025-03-13T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-early-feasibility-study-for-valcare-medical-s-amend-trans-septal-system-for-mitral-regurgitation 2025-03-13T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/proqr-advances-rna-editing-pipeline-with-four-clinical-readouts-expected-by-2026 2025-03-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proqr-advances-rna-editing-pipeline-with-four-clinical-readouts-expected-by-2026 2025-03-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-launches-promarkerd-revolutionary-predictive-test-for-diabetic-kidney-disease-in-australia 2025-03-13T11:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomics-international-launches-promarkerd-revolutionary-predictive-test-for-diabetic-kidney-disease-in-australia 2025-03-13T11:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/perfuze-secures-fda-clearance-for-zipline-access-catheters-and-eur22m-funding-for-stroke-treatment-innovation 2025-03-13T11:33:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perfuze-secures-fda-clearance-for-zipline-access-catheters-and-eur22m-funding-for-stroke-treatment-innovation 2025-03-13T11:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/new-endometriosis-pill-ryeqo-approved-for-nhs-use-offering-hope-to-1-5-million-uk-sufferers 2025-03-13T10:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-endometriosis-pill-ryeqo-approved-for-nhs-use-offering-hope-to-1-5-million-uk-sufferers 2025-03-13T10:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-approval-of-eli-lilly-s-alzheimer-s-drug-donanemab-requests-additional-safety-data 2025-03-13T10:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-approval-of-eli-lilly-s-alzheimer-s-drug-donanemab-requests-additional-safety-data 2025-03-13T10:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/arpis-show-similar-efficacy-in-mhspc-regardless-of-disease-volume-drug-selection-should-focus-on-patient-specific-factors 2025-03-13T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arpis-show-similar-efficacy-in-mhspc-regardless-of-disease-volume-drug-selection-should-focus-on-patient-specific-factors 2025-03-13T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/pranax-secures-md-anderson-exosome-technology-license-for-regenerative-medicine-applications 2025-03-13T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pranax-secures-md-anderson-exosome-technology-license-for-regenerative-medicine-applications 2025-03-13T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/paragonix-secures-eu-mdr-approval-for-five-organ-preservation-devices-expanding-european-market-access 2025-03-13T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paragonix-secures-eu-mdr-approval-for-five-organ-preservation-devices-expanding-european-market-access 2025-03-13T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ennodc-s-antibody-mediated-vaccines-show-promising-long-term-immunity-in-hiv-phase-i-trial 2025-03-13T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ennodc-s-antibody-mediated-vaccines-show-promising-long-term-immunity-in-hiv-phase-i-trial 2025-03-13T09:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-hormone-free-male-birth-control-pill-shows-99-efficacy-in-preclinical-studies 2025-03-13T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-hormone-free-male-birth-control-pill-shows-99-efficacy-in-preclinical-studies 2025-03-13T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/kane-biotech-advances-novel-dispersinb-r-acne-treatment-with-irb-approval-for-clinical-trial 2025-03-13T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kane-biotech-advances-novel-dispersinb-r-acne-treatment-with-irb-approval-for-clinical-trial 2025-03-13T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/st-vincent-s-melbourne-and-cmuh-forge-international-partnerships-to-advance-clinical-research 2025-03-13T07:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-vincent-s-melbourne-and-cmuh-forge-international-partnerships-to-advance-clinical-research 2025-03-13T07:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-merck-s-application-for-novel-two-drug-hiv-regimen-doravirine-islatravir 2025-03-13T07:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-merck-s-application-for-novel-two-drug-hiv-regimen-doravirine-islatravir 2025-03-13T07:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-cero-therapeutics-ind-for-novel-car-t-therapy-cer-1236-in-solid-tumors 2025-03-13T07:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-cero-therapeutics-ind-for-novel-car-t-therapy-cer-1236-in-solid-tumors 2025-03-13T07:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurogen-biomarking-partners-with-neurox-to-revolutionize-early-alzheimer-s-detection 2025-03-13T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurogen-biomarking-partners-with-neurox-to-revolutionize-early-alzheimer-s-detection 2025-03-13T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-invests-in-rocketvax-to-advance-next-generation-vaccine-development 2025-03-13T05:01:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emergent-biosolutions-invests-in-rocketvax-to-advance-next-generation-vaccine-development 2025-03-13T05:01:57+00:00 hourly 0.9 https://trial.medpath.com/news/florida-clinical-trial-facility-owners-plead-guilty-to-falsifying-asthma-drug-study-data 2025-03-13T04:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-clinical-trial-facility-owners-plead-guilty-to-falsifying-asthma-drug-study-data 2025-03-13T04:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/neural-therapeutics-advances-ethnobotanical-drug-discovery-platform-for-substance-use-disorders 2025-03-13T04:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neural-therapeutics-advances-ethnobotanical-drug-discovery-platform-for-substance-use-disorders 2025-03-13T04:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/third-arc-bio-initiates-phase-1-trial-of-novel-t-cell-engager-arc101-for-cldn6-positive-cancers 2025-03-13T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/third-arc-bio-initiates-phase-1-trial-of-novel-t-cell-engager-arc101-for-cldn6-positive-cancers 2025-03-13T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-advances-nmda-platform-with-breakthrough-therapies-for-suicidal-depression-and-chronic-pain 2025-03-13T03:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-advances-nmda-platform-with-breakthrough-therapies-for-suicidal-depression-and-chronic-pain 2025-03-13T03:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/significant-gaps-in-hiv-care-for-children-and-adolescents-require-urgent-attention 2025-03-13T02:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/significant-gaps-in-hiv-care-for-children-and-adolescents-require-urgent-attention 2025-03-13T02:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/donanemab-treatment-for-alzheimer-s-disease-linked-to-significant-aria-risk-analysis-reveals 2025-03-13T01:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/donanemab-treatment-for-alzheimer-s-disease-linked-to-significant-aria-risk-analysis-reveals 2025-03-13T01:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/muscular-dystrophy-research-reaches-turning-point-regeneration-emerges-as-next-frontier 2025-03-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/muscular-dystrophy-research-reaches-turning-point-regeneration-emerges-as-next-frontier 2025-03-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-blenrep-secures-uk-approval-for-multiple-myeloma-treatment-in-combination-therapy 2025-03-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-blenrep-secures-uk-approval-for-multiple-myeloma-treatment-in-combination-therapy 2025-03-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-s-mid-stage-study-demonstrates-robust-hiv-viral-suppression-with-long-acting-therapy 2025-03-12T23:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viiv-healthcare-s-mid-stage-study-demonstrates-robust-hiv-viral-suppression-with-long-acting-therapy 2025-03-12T23:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/actinium-pharmaceuticals-initiates-novel-triplet-therapy-trial-for-frontline-aml-treatment 2025-03-12T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-initiates-novel-triplet-therapy-trial-for-frontline-aml-treatment 2025-03-12T22:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/bloom-science-and-ascletis-report-promising-results-in-obesity-treatment-trials 2025-03-12T20:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bloom-science-and-ascletis-report-promising-results-in-obesity-treatment-trials 2025-03-12T20:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/vivani-medical-to-spin-off-cortigent-neurostimulation-business-as-independent-public-company 2025-03-12T20:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivani-medical-to-spin-off-cortigent-neurostimulation-business-as-independent-public-company 2025-03-12T20:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-converts-19-5m-debt-to-equity-advances-phase-2b-trial-of-non-opioid-pain-treatment 2025-03-12T20:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogwood-therapeutics-converts-19-5m-debt-to-equity-advances-phase-2b-trial-of-non-opioid-pain-treatment 2025-03-12T20:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/urogen-s-ugn-102-nears-fda-approval-with-impressive-phase-3-results-for-bladder-cancer 2025-03-12T20:03:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urogen-s-ugn-102-nears-fda-approval-with-impressive-phase-3-results-for-bladder-cancer 2025-03-12T20:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/nash-pipeline-shows-promise-with-80-emerging-therapies-in-development 2025-03-12T20:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nash-pipeline-shows-promise-with-80-emerging-therapies-in-development 2025-03-12T20:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-addition-to-docetaxel-shows-no-benefit-in-metastatic-castration-resistant-prostate-cancer 2025-03-12T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pembrolizumab-addition-to-docetaxel-shows-no-benefit-in-metastatic-castration-resistant-prostate-cancer 2025-03-12T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/ensitrelvir-shows-67-reduction-in-covid-19-risk-as-first-effective-post-exposure-prophylaxis-in-phase-3-trial 2025-03-12T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensitrelvir-shows-67-reduction-in-covid-19-risk-as-first-effective-post-exposure-prophylaxis-in-phase-3-trial 2025-03-12T19:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/new-antiviral-drug-ensitrelvir-shows-promise-in-preventing-covid-19-after-household-exposure 2025-03-12T19:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-antiviral-drug-ensitrelvir-shows-promise-in-preventing-covid-19-after-household-exposure 2025-03-12T19:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-s-n6ls-broadly-neutralizing-antibody-shows-promise-in-hiv-long-acting-treatment 2025-03-12T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viiv-healthcare-s-n6ls-broadly-neutralizing-antibody-shows-promise-in-hiv-long-acting-treatment 2025-03-12T19:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/seismic-therapeutic-advances-clinical-programs-with-dosing-of-healthy-subjects-in-two-phase-i-trials 2025-03-12T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seismic-therapeutic-advances-clinical-programs-with-dosing-of-healthy-subjects-in-two-phase-i-trials 2025-03-12T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/gc-cell-doses-first-patient-in-phase-1-trial-of-novel-cd5-car-nk-cell-therapy-for-t-cell-lymphoma 2025-03-12T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-cell-doses-first-patient-in-phase-1-trial-of-novel-cd5-car-nk-cell-therapy-for-t-cell-lymphoma 2025-03-12T19:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-expands-molecular-glue-portfolio-with-2-billion-monte-rosa-partnership 2025-03-12T17:02:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-expands-molecular-glue-portfolio-with-2-billion-monte-rosa-partnership 2025-03-12T17:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/legend-biotech-reports-strong-carvykti-r-growth-with-963-million-in-2024-sales-treating-over-5000-patients 2025-03-12T16:36:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legend-biotech-reports-strong-carvykti-r-growth-with-963-million-in-2024-sales-treating-over-5000-patients 2025-03-12T16:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/shuttle-pharmaceuticals-secures-5-75-million-in-public-offering-to-advance-cancer-radiation-therapy-research 2025-03-12T16:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shuttle-pharmaceuticals-secures-5-75-million-in-public-offering-to-advance-cancer-radiation-therapy-research 2025-03-12T16:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nanogel-delivery-system-shows-promise-for-treating-recurrent-utis 2025-03-12T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nanogel-delivery-system-shows-promise-for-treating-recurrent-utis 2025-03-12T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/lenacapavir-and-broadly-neutralizing-antibodies-show-promise-as-twice-yearly-hiv-treatment 2025-03-12T16:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenacapavir-and-broadly-neutralizing-antibodies-show-promise-as-twice-yearly-hiv-treatment 2025-03-12T16:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/bipolar-depression-market-set-to-grow-through-2034-with-new-therapies-in-pipeline 2025-03-12T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipolar-depression-market-set-to-grow-through-2034-with-new-therapies-in-pipeline 2025-03-12T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/repurposing-losartan-hypertension-drug-shows-promise-for-treating-epidermolysis-bullosa-in-children 2025-03-12T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repurposing-losartan-hypertension-drug-shows-promise-for-treating-epidermolysis-bullosa-in-children 2025-03-12T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-elute-s-bonvie-a-novel-resorbable-bone-void-filler-addressing-limitations-of-current-options 2025-03-12T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-elute-s-bonvie-a-novel-resorbable-bone-void-filler-addressing-limitations-of-current-options 2025-03-12T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/cs-diagnostics-enlists-lachman-consultants-to-secure-fda-approval-for-novel-cancer-treatment-hydrogel 2025-03-12T16:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cs-diagnostics-enlists-lachman-consultants-to-secure-fda-approval-for-novel-cancer-treatment-hydrogel 2025-03-12T16:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/corvus-pharmaceuticals-initiates-phase-2-trial-of-soquelitinib-for-rare-genetic-disease-alps 2025-03-12T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-initiates-phase-2-trial-of-soquelitinib-for-rare-genetic-disease-alps 2025-03-12T16:32:58+00:00 hourly 0.9